S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“

Christoph Sarrazin; Tim Zimmermann; Thomas Berg; Ulf Peter Neumann; Peter Schirmacher; Hartmut Schmidt; Ulrich Spengler; Jörg Timm; Heiner Wedemeyer; Stefan Wirth; Stefan Zeuzem; Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS); Deutsche Gesellschaft für Pathologie e.V. (DGP); Deutsche Leberstiftung; Gesellschaft für Virologie e.V. (GfV); Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE); Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH); Schweizerische Gesellschaft für Gastroenterologie (SGG); Deutsche Transplantationsgesellschaft e.V. (DTG); Deutsche Leberhilfe e.V.; Deutsche Gesellschaft für Infektiologie e.V. (DGI); Deutsche Gesellschaft für Suchtmedizin e.V. (DGS); Deutsche AIDS-Gesellschaft e.V. (DAIG); Deutsche Arbeitsgemeinschaft niedergelassener Ärzte für die Versorgung HIV-Infizierter (DAGNÄ); Robert Koch-Institut

doi:10.1055/a-0599-1320

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2018; 56(07): 756-838
DOI: 10.1055/a-0599-1320

Leitlinie

S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“

AWMF-Register-Nr.: 021/012Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infectionAWMF-Register-No.: 021/012

Christoph Sarrazin^*

¹Medizinische Klinik II mit Schwerpunkt Gastroenterologie, Hepatologie, Infektiologie, Diabetologie und Ernährungsmedizin, St. Josefs-Hospital, Wiesbaden, Germany

,

Tim Zimmermann^*

²Gastroenterologie und Hepatologie, Johannes Gutenberg Universität Mainz, I. Medizinische Klinik und Poliklinik, Mainz, Germany

,

Thomas Berg

³Klinik für Gastroenterologie und Rheumatologie, Sektion Hepatologie, Universitätsklinikum Leipzig, Germany

,

Ulf Peter Neumann

⁴Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Fakultät der RWTH Aachen, Germany

,

Peter Schirmacher

⁵Pathologisches Institut, Ruprecht Karls Universität Heidelberg Medizinische Fakultät Heidelberg, Germany

,

Hartmut Schmidt

⁶Medizinische Klinik B für Gastroenterologie und Hepatologie, Westfälische Wilhelms Universität Münster Medizinische Fakultät, Münster, Germany

,

Ulrich Spengler

⁷Gastroenterologie, Uniklinik Bonn, Germany

,

Jörg Timm

⁸Institut für Virologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Germany

,

Heiner Wedemeyer

⁹Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Essen, Germany

,

Stefan Wirth

¹⁰Helios Klinikum Wuppertal, Germany

,

Stefan Zeuzem

¹¹Medizinische Klinik I, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany

› Author Affiliationsin Kooperation mit folgenden Fachgesellschaften und Organisationen/Institutionen: Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Deutsche Gesellschaft für Pathologie e.V. (DGP), Deutsche Leberstiftung, Gesellschaft für Virologie e.V. (GfV), Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE), Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH), Schweizerische Gesellschaft für Gastroenterologie (SGG), Deutsche Transplantationsgesellschaft e.V. (DTG), Deutsche Leberhilfe e.V., Deutsche Gesellschaft für Infektiologie e.V. (DGI), Deutsche Gesellschaft für Suchtmedizin e.V. (DGS), Deutsche AIDS-Gesellschaft e.V. (DAIG), Deutsche Arbeitsgemeinschaft niedergelassener Ärzte für die Versorgung HIV-Infizierter (DAGNÄ), Robert Koch-Institut

Abstract

Full Text

References

Literatur
1 Wolffram I, Petroff D, Batz O. et al. Prevalence of elevated ALT values, HBsAg, and Anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J Hepatol 2015; 62: 1256-1264
2 de Martel C, Maucort-Boulch D, Plummer M. et al. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 2015; 62: 1190-1200
3 Perz JF, Armstrong GL, Farrington LA. et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538
4 Massard J, Ratziu V, Thabut D. et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44: S19-24
5 Niederau C, Lange S, Heintges T. et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-1695
6 Muhlberger N, Schwarzer R, Lettmeier B. et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC public health 2009; 9: 34
7 Poethko-Muller C, Zimmermann R, Hamouda O. et al. Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2013; 56: 707-715
8 Bruggmann P, Berg T, Ovrehus AL. et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. Journal of viral hepatitis 2014; 21 (Suppl. 01) 5-33
9 Palitzsch KD, Hottentrager B, Schlottmann K. et al. Prevalence of antibodies against hepatitis C virus in the adult German population. European journal of gastroenterology & hepatology 1999; 11: 1215-1220
10 Vermehren J, Schlosser B, Domke D. et al. High prevalence of Anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients. PloS one 2012; 7: e41206
11 Russmann S, Dowlatshahi EA, Printzen G. et al. Prevalence and associated factors of viral hepatitis and transferrin elevations in 5036 patients admitted to the emergency room of a Swiss university hospital: cross-sectional study. BMC gastroenterology 2007; 7: 5
12 Offergeld R, Ritter S, Hamouda O. HIV, HCV, HBV and syphilis surveillance among blood donors in Germany 2008–2010. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2012; 55: 907-913
13 Hinrichsen H, Leimenstoll G, Stegen G. et al. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002; 51: 429-433
14 Ross RS, Viazov S, Clauberg R. et al. Lack of de novo hepatitis C virus infections and absence of nosocomial transmissions of GB virus C in a large cohort of German haemodialysis patients. Journal of viral hepatitis 2009; 16: 230-238
15 Mederacke I, Meier M, Luth JB. et al. Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association 2011; 26: 2648-2656
16 Zimmermann R. HIV, Hepatitis B und C bei injizierenden Drogengebrauchenden in Deutschland – Ergebnisse der DRUCK-Studie des RKI. Epidemiologische Bulletin 2015: 22
17 Wenz B, Nielsen S, Gassowski M. et al. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011–14). BMC public health 2016; 16: 927
18 Kühne A, Zimmermann R. Hepatitis C im Jahr 2014. Epidemiologische Bulletin 2015: 30
19 (RKI)RK-I. Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Hepatitis C im Jahr 2015. Epid Bull 2016; 29
20 Meyer MF, Wedemeyer H, Monazahian M. et al. Prevalence of hepatitis C in a German prison for young men in relation to country of birth. Epidemiology and infection 2007; 135: 274-280
21 Schulte B, Stover H, Thane K. et al. Substitution treatment and HCV/HIV-infection in a sample of 31 German prisons for sentenced inmates. International journal of prisoner health 2009; 5: 39-44
22 Carney K, Dhalla S, Aytaman A. et al. Association of tattooing and hepatitis C virus infection: a multicenter case-control study. Hepatology 2013; 57: 2117-2123
23 Tohme RA, Holmberg SD. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012; 54: 1167-1178
24 Ockenga J, Tillmann HL, Trautwein C. et al. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 1997; 27: 18-24
25 Reuter S, Oette M, Wilhelm FC. et al. Prevalence and characteristics of hepatitis B and C virus infections in treatment-naive HIV-infected patients. Medical microbiology and immunology 2011; 200: 39-49
26 Jansen K, Thamm M, Bock CT. et al. High Prevalence and High Incidence of Coinfection with Hepatitis B, Hepatitis C, and Syphilis and Low Rate of Effective Vaccination against Hepatitis B in HIV-Positive Men Who Have Sex with Men with Known Date of HIV Seroconversion in Germany. PloS one 2015; 10: e0142515
27 Jilg W, Hottentrager B, Weinberger K. et al. Prevalence of markers of hepatitis B in the adult German population. Journal of medical virology 2001; 63: 96-102
28 Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission?. Hepatology 2010; 52: 1497-1505
29 Petersen EE, Clemens R, Bock HL. et al. Hepatitis B and C in heterosexual patients with various sexually transmitted diseases. Infection 1992; 20: 128-131
30 Polywka S, Feucht H, Zollner B. et al. Hepatitis C virus infection in pregnancy and the risk of mother-to-child transmission. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1997; 16: 121-124
31 Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34: 223-229
32 Garcia-Tejedor A, Maiques-Montesinos V, Diago-Almela VJ. et al. Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers. European journal of obstetrics, gynecology, and reproductive biology 2015; 194: 173-177
33 Heidrich B, Cetindere A, Beyaz M. et al. High prevalence of hepatitis markers in immigrant populations: a prospective screening approach in a real-world setting. European journal of gastroenterology & hepatology 2014; 26: 1090-1097
34 Henderson DK. Managing occupational risks for hepatitis C transmission in the health care setting. Clinical microbiology reviews 2003; 16: 546-568
35 Westermann C, Peters C, Lisiak B. et al. The prevalence of hepatitis C among healthcare workers: a systematic review and meta-analysis. Occupational and environmental medicine 2015; 72: 880-888
36 Colin C, Lanoir D, Touzet S. et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. Journal of viral hepatitis 2001; 8: 87-95
37 Alter MJ, Kuhnert WL, Finelli L. et al. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports 2003; 52: 1-13, 15 quiz CE11–14
38 Hajarizadeh B, Grady B, Page K. et al. Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study. PloS one 2015; 10: e0122232
39 Grebely J, Page K, Sacks-Davis R. et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014; 59: 109-120
40 Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36: S65-73
41 Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 2001; 8: 200-206
42 Glynn SA, Wright DJ, Kleinman SH. et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005; 45: 994-1002
43 Ross RS, Viazov S, Salloum S. et al. Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. Journal of clinical microbiology 2010; 48: 1161-1168
44 Tobler LH, Stramer SL, Lee SR. et al. Performance of ORTHO HCV core antigen and trak-C assays for detection of viraemia in pre-seroconversion plasma and whole blood donors. Vox sanguinis 2005; 89: 201-207
45 Takaki A, Wiese M, Maertens G. et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nature medicine 2000; 6: 578-582
46 Chevaliez S, Rodriguez C, Pawlotsky JM. New virologic tools for management of chronic hepatitis B and C. Gastroenterology 2012; 142: 1303-1313 e1301
47 Wiesmann F, Naeth G, Sarrazin C. et al. Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors. Medical microbiology and immunology 2015; 204: 515-525
48 Vermehren J, Maasoumy B, Maan R. et al. Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; 62: 1228-1234
49 Fevery B, Susser S, Lenz O. et al. Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2015; 72: 133-140
50 Yoshida EM, Sulkowski MS, Gane EJ. et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 2015; 61: 41-45
51 Chen J, Florian J, Carter W. et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144: 1450-1455 e1452
52 Maasoumy B, Vermehren J, Welker MW. et al. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. J Hepatol 2016; 65: 473-482
53 Liu CH, Liang CC, Liu CJ. et al. Comparison of Abbott RealTime HCV-Genotype II with Versant line probe assay 2. 0 for hepatitis C virus genotyping. . Journal of clinical microbiology 2015; 53: 1754-1757
54 Verbeeck J, Stanley MJ, Shieh J. et al. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2. 0. Journal of clinical microbiology 2008; 46: 1901-1906
55 Mokhtari C, Ebel A, Reinhardt B. et al. Characterization of Samples Identified as Hepatitis C Virus Genotype 1 without Subtype by Abbott RealTime HCV-Genotype II Assay Using the New Abbott HCV-Genotype Plus RUO Test. Journal of clinical microbiology 2016; 54: 296-299
56 Benedet M, Adachi D, Wong A. et al. The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV-Genotype II assay: a 1 year analysis. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2014; 60: 301-304
57 Yang R, Cong X, Du S. et al. Performance comparison of the versant HCV genotype 2.0 assay (LiPA) and the abbott realtime HCV genotype II assay for detecting hepatitis C virus genotype 6. Journal of clinical microbiology 2014; 52: 3685-3692
58 Mallory MA, Lucic DX, Sears MT. et al. Evaluation of the Abbott realtime HCV genotype II RUO (GT II) assay with reference to 5'UTR, core and NS5B sequencing. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2014; 60: 22-26
59 Kalinina O, Norder H, Mukomolov S. et al. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. Journal of virology 2002; 76: 4034-4043
60 Hedskog C, Doehle B, Chodavarapu K. et al. Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology 2015; 61: 471-480
61 De Keukeleire S, Descheemaeker P, Reynders M. Diagnosis of hepatitis C virus genotype 2k/1b needs NS5B sequencing. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2015; 41: 1-2
62 Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002; 123: 1367-1384
63 American Gastroenterological A. American Gastroenterological Association medical position statement: evaluation of liver chemistry tests. Gastroenterology 2002; 123: 1364-1366
64 Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36: S57-S64
65 Gebo KA, Chander G, Jenckes MW. et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36: S84-S92
66 Stravitz RT, Heuman DM, Chand N. et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. The American journal of medicine 2008; 121: 119-126
67 Thompson CoonJ, Rogers G, Hewson P. et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health technology assessment 2007; 11: 1-206
68 Trevisani F, Santi V, Gramenzi A. et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis?. The American journal of gastroenterology 2007; 102: 2448-2457 quiz 2458
69 Schirmacher P, Fleig WE, Dienes HP. et al. Biopsy diagnosis of chronic hepatitis. Zeitschrift fur Gastroenterologie 2004; 42: 175-185
70 Friedrich-Rust M, Ong MF, Martens S. et al. Performance of transient elastografy for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974
71 Poynard T, Ratziu V, Charlotte F. et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 2001; 34: 730-739
72 Desmet VJ, Gerber M, Hoofnagle JH. et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520
73 Ishak K, Baptista A, Bianchi L. et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699
74 Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293
75 Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36: S152-S160
76 Fattovich G, Pantalena M, Zagni I. et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. The American journal of gastroenterology 2002; 97: 2886-2895
77 Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008; 134: 1699-1714
78 Bruix J, Sherman M, Practice GuidelinesCommittee AAftSoLD. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236
79 El-Serag HB, Marrero JA, Rudolph L. et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-1763
80 Greten TF, Papendorf F, Bleck JS. et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. British journal of cancer 2005; 92: 1862-1868
81 Schacherer D, Schoelmerich J, Zuber-Jerger I. The diagnostic approach to hepatocellular carcinoma. Zeitschrift fur Gastroenterologie 2007; 45: 1067-1074
82 Kubitschke A, Bader C, Tillmann HL. et al. Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?. Der Internist 2007; 48: 1165-1172
83 Frijstein G, Hortensius J, Zaaijer HL. Needlestick injuries and infectious patients in a major academic medical centre from 2003 to 2010. The Netherlands journal of medicine 2011; 69: 465-468
84 Tomkins SE, Elford J, Nichols T. et al. Occupational transmission of hepatitis C in healthcare workers and factors associated with seroconversion: UK surveillance data. Journal of viral hepatitis 2012; 19: 199-204
85 Sulkowski MS, Ray SC, Thomas DL. Needlestick transmission of hepatitis C. Jama 2002; 287: 2406-2413
86 Yazdanpanah Y, De Carli G, Migueres B. et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41: 1423-1430
87 Thorburn D, Roy K, Cameron SO. et al. Risk of hepatitis C virus transmission from patients to surgeons: model based on an unlinked anonymous study of hepatitis C virus prevalence in hospital patients in Glasgow. Gut 2003; 52: 1333-1338
88 Mosley JW, Operskalski EA, Tobler LH. et al. Viral and host factors in early hepatitis C virus infection. Hepatology 2005; 42: 86-92
89 Gerlach JT, Diepolder HM, Zachoval R. et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-88
90 Mosley JW, Operskalski EA, Tobler LH. et al. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. Journal of viral hepatitis 2008; 15: 120-128
91 Chung H, Kudo M, Kumada T. et al. Risk of HCV transmission after needlestick injury, and the efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel. Journal of gastroenterology 2003; 38: 877-879
92 Nukaya H, Ohno T, Sakakibara K. et al. Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment. Hepatology research : the official journal of the Japan Society of Hepatology 2007; 37: 179-185
93 Corey KE, Servoss JC, Casson DR. et al. Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers. Infection control and hospital epidemiology 2009; 30: 1000-1005
94 Ciesek S, Friesland M, Steinmann J. et al. How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. The Journal of infectious diseases 2010; 201: 1859-1866
95 Doerrbecker J, Friesland M, Ciesek S. et al. Inactivation and survival of hepatitis C virus on inanimate surfaces. The Journal of infectious diseases 2011; 204: 1830-1838
96 Deterding K, Wiegand J, Gruner N. et al. Medical procedures as a risk factor for HCV infection in developed countries: do we neglect a significant problem in medical care?. J Hepatol 2008; 48: 1019-1020 author reply 1020–1011
97 Leao JC, Teo CG, Porter SR. HCV infection: aspects of epidemiology and transmission relevant to oral health care workers. International journal of oral and maxillofacial surgery 2006; 35: 295-300
98 Germain JM, Carbonne A, Thiers V. et al. Patient-to-patient transmission of hepatitis C virus through the use of multidose vials during general anesthesia. Infection control and hospital epidemiology 2005; 26: 789-792
99 Forns X, Martinez-Bauer E, Feliu A. et al. Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology 2005; 41: 115-122
100 de Ledinghen V, Trimoulet P, Mannant PR. et al. Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). J Hepatol 2007; 46: 19-25
101 Kondili LA, Genovese D, Argentini C. et al. Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2006; 25: 527-531
102 Savey A, Simon F, Izopet J. et al. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infection control and hospital epidemiology 2005; 26: 752-760
103 Bronowicki JP, Venard V, Botte C. et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. The New England journal of medicine 1997; 337: 237-240
104 Quer J, Esteban JI, Sanchez JM. et al. Nosocomial transmission of hepatitis C virus during contrast-enhanced computed tomografy scanning. European journal of gastroenterology & hepatology 2008; 20: 73-78
105 Mehta A, Rodrigues C, Ghag S. et al. Needlestick injuries in a tertiary care centre in Mumbai, India. The Journal of hospital infection 2005; 60: 368-373
106 Oh HS, Yi SE, Choe KW. Epidemiological characteristics of occupational blood exposures of healthcare workers in a university hospital in South Korea for 10 years. The Journal of hospital infection 2005; 60: 269-275
107 Biostoffverordnung. Bundesgesetzblatt Teil I 1999; 50; 1999, 2059; 2003, 2304; 2004, 3758; 2004, 3758; 2006; 2407) sowie TRBA 250 Neufassung von Mai 2006. In. www.nadelstichverletzung.de
108 Department of Health L. Hepatitis C Infected Health Care Workers. In. http://www.doh.gov.uk
109 Roß RS, Roggendorf M. Empfehlungen der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) zur Prävention der nosokomialen Übertragung von Hepatitis B Virus (HBV) und Hepatitis C Virus (HCV) durch im Gesundheitswesen Tätige. (Stand: Juli 2007). Übertragungsrisiko von HBV, HCV und HIV durch infiziertes medizinisches Personal. Pabst Science Publishers; 2007 2. Auflage.
110 Gunson RN, Shouval D, Roggendorf M. et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2003; 27: 213-230
111 Duckworth GJ, Heptonstall J, Aitken C. Transmission of hepatitis C virus from a surgeon to a patient. The Incident Control Team. Communicable disease and public health 1999; 2: 188-192
112 Esteban JI, Gomez J, Martell M. et al. Transmission of hepatitis C virus by a cardiac surgeon. The New England journal of medicine 1996; 334: 555-560
113 Mawdsley J, Teo CG, Kyi M. et al. Anesthetist to patient transmission of hepatitis C virus associated with non exposure-prone procedures. Journal of medical virology 2005; 75: 399-401
114 [Anonym]. Hepatitis C virus transmission from health care worker to patient. Communicable disease report CDR weekly 1995; 5: 121
115 [Anonym]. Two hepatitis C lookback exercises--national and in London. Communicable disease report CDR weekly 2000; 10: 125-128
116 [Anonym]. Hepatitis C lookback exercise. Communicable disease report CDR weekly 2000; 10: 203-206
117 [Anonym]. Hepatitis C lookback in two trusts in the south of England. Commun Dis Rep CDR Weekly 2001; 11: 21
118 [Anonym]. Surgeon-to-patient HCV infections raise questions. Hospital employee health 2002;
119 Ross RS, Viazov S, Roggendorf M. Risk of hepatitis C transmission from infected medical staff to patients: model-based calculations for surgical settings. Archives of internal medicine 2000; 160: 2313-2316
120 Ross RS, Viazov S, Thormahlen M. et al. Risk of hepatitis C virus transmission from an infected gynecologist to patients: results of a 7-year retrospective investigation. Archives of internal medicine 2002; 162: 805-810
121 Ross RS, Viazov S, Khudyakov YE. et al. Transmission of hepatitis C virus in an orthopedic hospital ward. Journal of medical virology 2009; 81: 249-257
122 Ross RS, Viazov S, Roggendorf M. Phylogenetic analysis indicates transmission of hepatitis C virus from an infected orthopedic surgeon to a patient. Journal of medical virology 2002; 66: 461-467
123 Stark K, Hanel M, Berg T. et al. Nosocomial transmission of hepatitis C virus from an anesthesiologist to three patients--epidemiologic and molecular evidence. Archives of virology 2006; 151: 1025-1030
124 Williams IT, Perz JF, Bell BP. Viral hepatitis transmission in ambulatory health care settings. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004; 38: 1592-1598
125 Williams IT, Perz JF, Bell BP. Hepatitis C virus transmission from healthcare workers to patients in the USA. Journal of Clinical Virology 2006; 36: S43-S44
126 Said F, El Beshlawy A, Hamdy M. et al. Intrafamilial transmission of hepatitis C infection in Egyptian multitransfused thalassemia patients. Journal of tropical pediatrics 2013; 59: 309-313
127 Paez JimenezA, Sharaf EldinN, Rimlinger F. et al. HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut 2010; 59: 1554-1560
128 Ndong-Atome GR, Njouom R, Padilla C. et al. Absence of intrafamilial transmission of hepatitis C virus and low risk for sexual transmission in rural central Africa indicate a cohort effect. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2009; 45: 349-353
129 Keiserman DR, Both CT, Mattos AA. et al. Intrafamilial transmission of hepatitis C virus in patients with hepatitis C and human immunodeficiency virus coinfection. The American journal of gastroenterology 2003; 98: 878-883
130 Ackerman Z, Ackerman E, Paltiel O. Intrafamilial transmission of hepatitis C virus: a systematic review. Journal of viral hepatitis 2000; 7: 93-103
131 Plancoulaine S, Mohamed MK, Arafa N. et al. Dissection of familial correlations in hepatitis C virus (HCV) seroprevalence suggests intrafamilial viral transmission and genetic predisposition to infection. Gut 2008; 57: 1268-1274
132 Lock G, Dirscherl M, Obermeier F. et al. Hepatitis C – contamination of toothbrushes: myth or reality?. Journal of viral hepatitis 2006; 13: 571-573
133 Atas M, Karatepe Hashas AS, Demircan S. et al. The Investigation of HCV RNA in Tear Fluid and Aqueous Humor in Patients with Anti-HCV Antibody Positive Who Underwent Cataract Surgery. Ocular immunology and inflammation 2016; 24: 297-301
134 Xavier Santos RL, de Deus DM, de Almeida Lopes EP. et al. Evaluation of viral load in saliva from patients with chronic hepatitis C infection. Journal of infection and public health 2015; 8: 474-480
135 Heidrich B, Steinmann E, Plumeier I. et al. Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2016; 80: 1-7
136 Terrault NA, Dodge JL, Murphy EL. et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology 2013; 57: 881-889
137 Bourlet T, Levy R, Maertens A. et al. Detection and characterization of hepatitis C virus RNA in seminal plasma and spermatozoon fractions of semen from patients attempting medically assisted conception. Journal of clinical microbiology 2002; 40: 3252-3255
138 Farias A, Re V, Mengarelli S. et al. Detection of hepatitis C virus (HCV) in body fluids from HCV monoinfected and HCV/HIV coinfected patients. Hepato-gastroenterology 2010; 57: 300-304
139 Orlando R, Lirussi F. Hepatitis C virus infection: sexual or non-sexual transmission between spouses? A case report and review of the literature. Infection 2007; 35: 465-468
140 Wiegand J, Buggisch P, Boecher W. et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43: 250-256
141 Boonyarad V, Chutaputti A, Choeichareon S. et al. Interspousal transmission of hepatitis C in Thailand. Journal of gastroenterology 2003; 38: 1053-1059
142 Kao JH, Liu CJ, Chen PJ. et al. Low incidence of hepatitis C virus transmission between spouses: a prospective study. Journal of gastroenterology and hepatology 2000; 15: 391-395
143 Vandelli C, Renzo F, Romano L. et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. The American journal of gastroenterology 2004; 99: 855-859
144 La Torre G, Miele L, Mannocci A. et al. Correlates of HCV seropositivity among familial contacts of HCV positive patients. BMC public health 2006; 6: 237
145 McFaul K, Maghlaoui A, Nzuruba M. et al. Acute hepatitis C infection in HIV-negative men who have sex with men. Journal of viral hepatitis 2015; 22: 535-538
146 Ghisla V, Scherrer AU, Nicca D. et al. Incidence of hepatitis C in HIV positive and negative men who have sex with men 2000–2016: a systematic review and meta-analysis. Infection 2017; 45: 309-321
147 Bradshaw D, Matthews G, Danta M. Sexually transmitted hepatitis C infection: the new epidemic in MSM?. Current opinion in infectious diseases 2013; 26: 66-72
148 Boesecke C, Rockstroh JK. Acute hepatitis C in patients with HIV. Seminars in liver disease 2012; 32: 130-137
149 Yaphe S, Bozinoff N, Kyle R. et al. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sexually transmitted infections 2012; 88: 558-564
150 Boesecke C, Grint D, Soriano V. et al. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?. Liver international : official journal of the International Association for the Study of the Liver 2015; 35: 2384-2391
151 Hagan H, Jordan AE, Neurer J. et al. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. Aids 2015; 29: 2335-2345
152 Vanhommerig JW, Lambers FA, Schinkel J. et al. Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control Study. Open forum infectious diseases 2015; 2: ofv115
153 Kaplan-Lewis E, Fierer DS. Acute HCV in HIV-infected MSM: modes of acquisition, liver fibrosis, and treatment. Current HIV/AIDS reports 2015; 12: 317-325
154 Martin TC, Martin NK, Hickman M. et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. Aids 2013; 27: 2551-2557
155 Lambers FA, Prins M, Thomas X. et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. Aids 2011; 25: F21-F27
156 Wiessing L, Ferri M, Grady B. et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PloS one 2014; 9: e103345
157 Nelson PK, Mathers BM, Cowie B. et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet (London, England) 2011; 378: 571-583
158 Macias J, Palacios RB, Claro E. et al. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver international : official journal of the International Association for the Study of the Liver 2008; 28: 781-786
159 Tortu S, McMahon JM, Pouget ER. et al. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Substance use & misuse 2004; 39: 211-224
160 Fischer B, Powis J, Firestone CruzM. et al. Hepatitis C virus transmission among oral crack users: viral detection on crack paraphernalia. European journal of gastroenterology & hepatology 2008; 20: 29-32
161 Palmateer NE, Hutchinson SJ, Innes H. et al. Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. The International journal on drug policy 2013; 24: 85-100
162 Esmaeili A, Mirzazadeh A, Carter GM. et al. Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis. Journal of viral hepatitis 2017; 24: 117-127
163 Page-Shafer K, Hahn JA, Lum PJ. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. Aids 2007; 21: 1967-1969
164 Doerrbecker J, Behrendt P, Mateu-Gelabert P. et al. Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. The Journal of infectious diseases 2013; 207: 281-287
165 Fernandes RM, Cary M, Duarte G. et al. Effectiveness of needle and syringe Programmes in people who inject drugs – An overview of systematic reviews. BMC public health 2017; 17: 309
166 Jafari S, Copes R, Baharlou S. et al. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2010; 14: e928-e940
167 Garfein RS, Golub ET, Greenberg AE. et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. Aids 2007; 21: 1923-1932
168 Latka MH, Hagan H, Kapadia F. et al. A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C. American journal of public health 2008; 98: 853-861
169 Smith DJ, Combellick J, Jordan AE. et al. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. The International journal on drug policy 2015; 26: 911-921
170 Smith DJ, Jordan AE, Frank M. et al. Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis. BMC infectious diseases 2016; 16: 471
171 Midgard H, Bjoro B, Maeland A. et al. Hepatitis C reinfection after sustained virological response. J Hepatol 2016; 64: 1020-1026
172 Weir A, McLeod A, Innes H. et al. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. Drug and alcohol dependence 2016; 165: 53-60
173 Farci P, Munoz SJ, Shimoda A. et al. Experimental transmission of hepatitis C virus-associated fulminant hepatitis to a chimpanzee. The Journal of infectious diseases 1999; 179: 1007-1011
174 Farci P, Shimoda A, Coiana A. et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-344
175 Deterding K, Wiegand J, Gruner N. et al. The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Zeitschrift fur Gastroenterologie 2009; 47: 531-540
176 Jaeckel E, Cornberg M, Wedemeyer H. et al. Treatment of acute hepatitis C with interferon alfa-2b. The New England journal of medicine 2001; 345: 1452-1457
177 Deterding K, Gruner N, Buggisch P. et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. The Lancet Infectious diseases 2013; 13: 497-506
178 Deterding K, Spinner CD, Schott E. et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. The Lancet Infectious diseases 2017; 17: 215-222
179 Hullegie SJ, van den Berk GE, Leyten EM. et al. Acute hepatitis C in the Netherlands: characteristics of the epidemic in 2014. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2016; 22: 209 e201-203
180 Fierer DS, Dieterich DT, Mullen MP. et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014; 58: 873-879
181 Boesecke C, Singh GK, Scholten SH. et al. Telaprevir-containing triple therapy in acute HCV coinfection: The CHAT Study. Antiviral therapy 2017;
182 Rockstroh JK, Bhagani S, Hyland RH. et al. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. The lancet Gastroenterology & hepatology 2017; 2: 347-353
183 Martinello M, Gane E, Hellard M. et al. Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study. Hepatology 2016; 64: 1911-1921
184 Naggie S, Marks KM, Hughes M. et al. Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017; 64: 1035-1042
185 El SayedA, Barbati ZR, Turner SS. et al. Sofosbuvir in the treatment of early HCV infection in HIV-infected men. HIV clinical trials 2017; 18: 60-66
186 Amin J, Law MG, Bartlett M. et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet (London, England) 2006; 368: 938-945
187 Neal KR, Trent Hepatitis CSG, Ramsay S. et al. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56: 1098-1104
188 Marcellin P, Pequignot F, Delarocque-Astagneau E. et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48: 200-207
189 Davis GL, Albright JE, Cook SF. et al. Projecting future complications of chronic hepatitis C in the United States. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2003; 9: 331-338
190 Buti M, San Miguel R, Brosa M. et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42: 639-645
191 Sypsa V, Touloumi G, Papatheodoridis GV. et al. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. Journal of viral hepatitis 2005; 12: 543-550
192 Sweeting MJ, De Angelis D, Brant LJ. et al. The burden of hepatitis C in England. Journal of viral hepatitis 2007; 14: 570-576
193 El-Serag HB, Davila JA, Petersen NJ. et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Annals of internal medicine 2003; 139: 817-823
194 Tanaka Y, Kurbanov F, Mano S. et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 2006; 130: 703-714
195 Ly KN, Xing J, Klevens RM. et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Annals of internal medicine 2012; 156: 271-278
196 Cowie BC, Allard N, MacLachlan JH. European Responses in Focus: Comparing Viral Hepatitis and Hiv Related Deaths in Europe 1990–2010 in the Global Burden of Disease Study 2010. Journal of hepatology 2014; 60: S35-S36
197 Sixty-Third World Health Assembly WHO. Viral Hepatitis. WHA; 2010 63.18
198 [Anonym]. World Health Organization. Global policy report on the prevention and control of viral hepatitis. 2013
199 Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26: 21S-28S
200 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. . Lancet (London, England) 1997; 349: 825-832
201 Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26: 34S-38S
202 Sangiovanni A, Prati GM, Fasani P. et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310
203 Huang YT, Jen CL, Yang HI. et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011; 29: 3643-3650
204 Bochud PY, Cai T, Overbeck K. et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-666
205 Freeman AJ, Dore GJ, Law MG. et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816
206 Pessione F, Degos F, Marcellin P. et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27: 1717-1722
207 Ghany MG, Kleiner DE, Alter H. et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104
208 Ryder SD, Irving WL, Jones DA. et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53: 451-455
209 Hui CK, Belaye T, Montegrande K. et al. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003; 38: 511-517
210 Adinolfi LE, Gambardella M, Andreana A. et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364
211 Thein HH, Yi Q, Dore GJ. et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-431
212 Lee MH, Yang HI, Lu SN. et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28: 4587-4593
213 Rueger S, Bochud PY, Dufour JF. et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut 2015; 64: 1605-1615
214 Patin E, Kutalik Z, Guergnon J. et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 2012; 143: 1244-1252 e1241–1212
215 Alberti A, Benvegnu L. Management of hepatitis c. Journal of hepatology 2003; 38: S104-S118
216 Wilson LE, Torbenson M, Astemborski J. et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 2006; 43: 788-795
217 Zarski JP, Mc HutchisonJ, Bronowicki JP. et al. Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol 2003; 38: 307-314
218 Zeuzem S, Diago M, Gane E. et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-1732
219 Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-212
220 Cordoba J, Flavia M, Jacas C. et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003; 39: 231-238
221 Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. Journal of viral hepatitis 2003; 10: 81-86
222 Carta MG, Hardoy MC, Garofalo A. et al. Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clinical practice and epidemiology in mental health : CP & EMH 2007; 3: 22
223 Perry W, Hilsabeck RC, Hassanein TI. Cognitive dysfunction in chronic hepatitis C: a review. Digestive diseases and sciences 2008; 53: 307-321
224 Acharya JN, Pacheco VH. Neurologic complications of hepatitis C. The neurologist 2008; 14: 151-156
225 Weissenborn K, Krause J, Bokemeyer M. et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41: 845-851
226 Weissenborn K, Ennen JC, Bokemeyer M. et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 2006; 55: 1624-1630
227 Younossi ZM, Stepanova M, Pol S. et al. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver international : official journal of the International Association for the Study of the Liver 2016; 36: 42-48
228 Younossi ZM, Stepanova M, Nader F. et al. Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens. Journal of the American Geriatrics Society 2016; 64: 386-393
229 Younossi ZM, Stepanova M, Feld J. et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. J Hepatol 2016; 65: 33-39
230 Younossi ZM, Birerdinc A, Henry L. Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. J Hepatol 2016; 65: S109-S119
231 Cacoub P, Poynard T, Ghillani P. et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis and rheumatism 1999; 42: 2204-2212
232 Ferri C, Antonelli A, Mascia MT. et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2007; 39 (Suppl. 01) S13-S21
233 Zignego AL, Ferri C, Pileri SA. et al. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2007; 39: 2-17
234 Younossi Z, Park H, Henry L. et al. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology 2016; 150: 1599-1608
235 Hermine O, Lefrere F, Bronowicki JP. et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. The New England journal of medicine 2002; 347: 89-94
236 Mele A, Pulsoni A, Bianco E. et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003; 102: 996-999
237 Duberg AS, Nordstrom M, Torner A. et al. Non-Hodgkin’s lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 2005; 41: 652-659
238 Morton LM, Engels EA, Holford TR. et al. Hepatitis C virus and risk of non-Hodgkin lymphoma: a population-based case-control study among Connecticut women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004; 13: 425-430
239 Zignego AL, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World journal of gastroenterology 2007; 13: 2467-2478
240 Giordano TP, Henderson L, Landgren O. et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. Jama 2007; 297: 2010-2017
241 Hartridge-Lambert SK, Stein EM, Markowitz AJ. et al. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology 2012; 55: 634-641
242 Allison RD, Tong X, Moorman AC. et al. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006–2010. J Hepatol 2015; 63: 822-828
243 White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 831-844
244 Naing C, Mak JW, Ahmed SI. et al. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World journal of gastroenterology 2012; 18: 1642-1651
245 Petta S, Camma C, Scazzone C. et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 1158-1167
246 Lange CM, Bojunga J, Ramos-Lopez E. et al. Vitamin D deficiency and a CYP27B1–1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54: 887-893
247 Lin JC, Hsieh TY, Wu CC. et al. Association between chronic hepatitis C virus infection and bone mineral density. Calcified tissue international 2012; 91: 423-429
248 Mansueto P, Carroccio A, Seidita A. et al. Osteodystrophy in chronic liver diseases. Internal and emergency medicine 2013; 8: 377-388
249 Yadav A, Carey EJ. Osteoporosis in chronic liver disease. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2013; 28: 52-64
250 Gatta A, Verardo A, Di Pascoli M. et al. Hepatic osteodystrophy. Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases 2014; 11: 185-191
251 Nakchbandi IA. Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implications. World journal of gastroenterology 2014; 20: 9427-9438
252 Castronuovo D, Cacopardo B, Pinzone MR. et al. Bone disease in the setting of HIV infection: update and review of the literature. European review for medical and pharmacological sciences 2013; 17: 2413-2419
253 Del Carpio-Cano FE, Dela Cadena RA, Sawaya BE. HIV and Bone Disease: A Perspective of the Role of microRNAs in Bone Biology upon HIV Infection. Journal of osteoporosis 2013; 2013: 571418
254 Rothman MS, Bessesen MT. HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options. Current osteoporosis reports 2012; 10: 270-277
255 Saccomanno MF, Ammassari A. Bone disease in HIV infection. Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases 2011; 8: 33-36
256 Yin MT, Zhang CA, McMahon DJ. et al. Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. The Journal of clinical endocrinology and metabolism 2012; 97: 554-562
257 Compston J. HIV infection and osteoporosis. BoneKEy reports 2015; 4: 636
258 Teichmann J, Stephan E, Lange U. et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. The Journal of infection 2003; 46: 221-227
259 Lo Re 3rd V, Volk J. et al. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology 2012; 56: 1688-1698
260 Maalouf NM, Zhang S, Drechsler H. et al. Hepatitis C co-infection and severity of liver disease as risk factors for osteoporotic fractures among HIV-infected patients. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2013; 28: 2577-2583
261 Lo Re 3rd V, Lynn K. et al. Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women. The Journal of infectious diseases 2015; 212: 924-933
262 Mazzotta E, Ursini T, Agostinone A. et al. Prevalence and predictors of low bone mineral density and fragility fractures among HIV-infected patients at one Italian center after universal DXA screening: sensitivity and specificity of current guidelines on bone mineral density management. AIDS patient care and STDs 2015; 29: 169-180
263 Dong HV, Cortes YI, Shiau S. et al. Osteoporosis and fractures in HIV/hepatitis C virus coinfection: a systematic review and meta-analysis. Aids 2014; 28: 2119-2131
264 Lai JC, Shoback DM, Zipperstein J. et al. Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C. Digestive diseases and sciences 2015; 60: 1813-1819
265 Marek B, Kajdaniuk D, Niedziolka D. et al. Growth hormone/insulin-like growth factor-1 axis, calciotropic hormones and bone mineral density in young patients with chronic viral hepatitis. Endokrynologia Polska 2015; 66: 22-29
266 Gaudio A, Pennisi P, Muratore F. et al. Reduction of volumetric bone mineral density in postmenopausal women with hepatitis C virus-correlated chronic liver disease: a peripheral quantitative computed tomografy (pQCT) study. European journal of internal medicine 2012; 23: 656-660
267 Chen CH, Lin CL, Kao CH. Relation Between Hepatitis C Virus Exposure and Risk of Osteoporosis: A Nationwide Population-Based Study. Medicine 2015; 94: e2086
268 Hansen AB, Omland LH, Krarup H. et al. Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study. J Hepatol 2014; 61: 15-21
269 Hsu YH, Muo CH, Liu CY. et al. Hepatitis C virus infection increases the risk of developing peripheral arterial disease: a 9-year population-based cohort study. J Hepatol 2015; 62: 519-525
270 Lee MH, Yang HI, Lu SN. et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. The Journal of infectious diseases 2012; 206: 469-477
271 Lee MH, Yang HI, Wang CH. et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010; 41: 2894-2900
272 Petta S, Maida M, Macaluso FS. et al. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology 2016; 150: 145-155 e144; quiz e115–146
273 Jezequel C, Bardou-Jacquet E, Desille Y. et al. Survival of Patients Infected by Chronic Hepatitis C and F0f1 Fibrosis at Baseline after a 15 Years Follow-Up. Journal of hepatology 2015; 62: S589-S589
274 Manns M, Samuel D, Gane EJ. et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. The Lancet Infectious diseases 2016; 16: 685-697
275 Poordad F, Schiff ER, Vierling JM. et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016; 63: 1493-1505
276 Afdhal N, Everson GT, Calleja JL. et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. Journal of viral hepatitis 2017;
277 Charlton M, Everson GT, Flamm SL. et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 2015; 149: 649-659
278 Curry MP, O’Leary JG, Bzowej N. et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. The New England journal of medicine 2015; 373: 2618-2628
279 Foster GR, Irving WL, Cheung MC. et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 64: 1224-1231
280 Charlton M, Everson GT, Flamm SL. et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 2015; 149: 649-659
281 Manns M, Samuel D, Gane EJ. et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. The Lancet Infectious diseases 2016;
282 Poordad F, Schiff ER, Vierling JM. et al. Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence. Hepatology 2016;
283 Belli LS, Berenguer M, Cortesi PA. et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 2016; 65: 524-531
284 Coilly A, Pageaux GP, Houssel-Debry P. et al. Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAA?. Hepatology 2015; 62: 257a-257a
285 Zimmermann T, Beckebaum S, Berg C. et al. Expert recommendations: Hepatitis C and transplantation. Zeitschrift fur Gastroenterologie 2016; 54: 665-684
286 Pawlotsky JM, Aghemo A, Back D. et al. EASL Recommendations on Treatment of Hepatitis C 2015. Journal of hepatology 2015; 63: 199-236
287 Reig M, Marino Z, Perello C. et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65: 719-726
288 Conti F, Buonfiglioli F, Scuteri A. et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65: 727-733
289 stanislas.pol@aphp.fr AcsgohcEa. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 2016; 65: 734-740
290 Cheung MC, Walker AJ, Hudson BE. et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 65: 741-747
291 Vallisa D, Bernuzzi P, Arcaini L. et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23: 468-473
292 Sterling RK, Sanyal AJ, Luketic VA. et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. The American journal of gastroenterology 1999; 94: 3576-3582
293 Glicklich D, Thung SN, Kapoian T. et al. Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients. The American journal of gastroenterology 1999; 94: 159-163
294 Martin P, Carter D, Fabrizi F. et al. Histopathological features of hepatitis C in renal transplant candidates [see comment]. Transplantation 2000; 69: 1479-1484
295 Cotler SJ, Diaz G, Gundlapalli S. et al. Characteristics of hepatitis C in renal transplant candidates. Journal of clinical gastroenterology 2002; 35: 191-195
296 Hu KQ, Lee SM, Hu SX. et al. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. The American journal of gastroenterology 2005; 100: 2010-2018
297 Fabrizi F, Martin P, Dixit V. et al. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Alimentary pharmacology & therapeutics 2004; 20: 1271-1277
298 Di Napoli A, Di Lallo D, Pezzotti P. et al. Effects of parental smoking and level of education on initiation and duration of breastfeeding. Acta paediatrica 2006; 95: 678-685
299 Pereira BJ, Natov SN, Bouthot BA. et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney international 1998; 53: 1374-1381
300 Baid-Agrawal S, Pascual M, Moradpour D. et al. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Reviews in medical virology 2008; 18: 97-115
301 Cacoub P, Desbois AC, Isnard-Bagnis C. et al. Hepatitis C virus infection and chronic kidney disease: Time for reappraisal. J Hepatol 2016; 65: S82-S94
302 Fabrizi F, Martin P, Dixit V. et al. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2005; 5: 1452-1461
303 el-Serag HB, Kunik M, Richardson P. et al. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123: 476-482
304 Schaefer M, Capuron L, Friebe A. et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 2012; 57: 1379-1390
305 Ghany MG, Strader DB, Thomas DL. et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374
306 Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. The Lancet Infectious diseases 2005; 5: 558-567
307 Schaefer M, Sarkar R, Diez-Quevedo C. Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013; 57 (Suppl. 02) S111-S117
308 Wittchen HU, Rehm JT, Gölz J. et al. Schlussfolgerungen und Empfehlungen für eine bedarfs- und zielgruppengerechtere Gestaltung der langfristigen Substitution Opioidabhängiger (PREMOS-Studie). Suchtmed 2011; 13: 287-239
309 Robaeys G, Grebely J, Mauss S. et al. Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. Clinical Infectious Diseases 2013; 57: S129-S137
310 Grebely J, Robaeys G, Bruggmann P. et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy 2015; 26: 1028-1038
311 Lalezari J, Sullivan JG, Varunok P. et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol 2015; 63: 364-369
312 Mangia A, Kugelmas M, Everson GT. et al. Virologic Response Rates to Sofosbuvir-Containing Regimens Are Similar in Patients With and Without Traditional Negative Predictive Factors: A Retrospective Analysis of Phase 3 Data. Hepatology 2013; 58: 752a-753a
313 Puoti M, Cooper C, Sulkowski MS. et al. ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV-Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials. Hepatology 2014; 60: 1135a-1136a
314 Martin NK, Foster GR, Vilar J. et al. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. Journal of viral hepatitis 2015; 22: 399-408
315 Afdhal N, Zeuzem S, Kwo P. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. The New England journal of medicine 2014; 370: 1889-1898
316 Bourliere M, Sulkowski MS, Omata M. et al. An Integrated Safety and Efficacy Analysis of > 500 Patients with Compensated Cirrhosis Treated with Ledipasvir/Sofosbuvir with or without Ribavirin. Hepatology 2014; 60: 239a-239a
317 Kowdley KV, Gordon SC, Reddy KR. et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. The New England journal of medicine 2014; 370: 1879-1888
318 Buggisch P, Boker KHW, Gunther R. et al. Ledipasvir/Sofosbuvir Treatment for 8 Weeks in Treatment-Naive Hcv Genotype 1 Infected Patients under Real Life Conditions: Data from the German Hepatitis C-Registry (Dhc-R). Journal of hepatology 2016; 64: S810-S810
319 Afdhal N, Reddy KR, Nelson DR. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. The New England journal of medicine 2014; 370: 1483-1493
320 Feld JJ, Jacobson IM, Hezode C. et al. Sofosbuvir and Velpatasvir for HCV-Genotype 1, 2, 4, 5, and 6 Infection. The New England journal of medicine 2015; 373: 2599-2607
321 Everson GT, Towner WJ, Davis MN. et al. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Annals of internal medicine 2015; 163: 818-826
322 Ferenci P, Bernstein D, Lalezari J. et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. The New England journal of medicine 2014; 370: 1983-1992
323 Feld JJ, Kowdley KV, Coakley E. et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. The New England journal of medicine 2014; 370: 1594-1603
324 Poordad F, Hezode C, Trinh R. et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. The New England journal of medicine 2014; 370: 1973-1982
325 Everson GT, Dusheiko G, Coakley E. et al. Integrated Efficacy Analysis of Four Phase 3 Studies in HCV-Genotype 1a-Infected Patients Treated with ABT450/r/Ombitasvir and Dasabuvir With or Without Ribavirin. Hepatology 2014; 60: 239a-240a
326 Feld JJ, Moreno C, Trinh R. et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol 2016; 64: 301-307
327 Welzel TM, Zeuzem S, Dumas EO. et al. GARNET: High SVR Rates Following Eight-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir for Patients with HCV-Genotype 1b Infection. American Journal of Gastroenterology 2016; 111: S388-S388
328 Zeuzem S, Jacobson IM, Baykal T. et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. The New England journal of medicine 2014; 370: 1604-1614
329 Andreone P, Colombo MG, Enejosa JV. et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359-365 e351
330 Zeuzem S, Ghalib R, Reddy KR. et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Annals of internal medicine 2015; 163: 1-13
331 Kwo P, Gane E, Peng CY. et al. EFFICACY AND SAFETY OF GRAZOPREVIR/ELBASVIR plus /- RBV FOR 12 WEEKS IN PATIENTS WITH HCV G1 OR G4 INFECTION WHO PREVIOUSLY FAILED PEGINTERFERON/RBV: C-EDGE TREATMENT-EXPERIENCED TRIAL. Journal of hepatology 2015; 62: S674-S675
332 Peiffer KH, Sommer L, Susser S. et al. Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. Hepatology 2016; 63: 63-73
333 Buti M, Gordon SC, Zuckerman E. et al. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; 62: 32-36
334 Sulkowski MS, Gardiner DF, Rodriguez-Torres M. et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. The New England journal of medicine 2014; 370: 211-221
335 Wyles DL, Ruane PJ, Sulkowski MS. et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. The New England journal of medicine 2015; 373: 714-725
336 Lawitz E, Matusow G, DeJesus E. et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 2016; 64: 360-369
337 Lawitz E, Sulkowski MS, Ghalib R. et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet (London, England) 2014; 384: 1756-1765
338 Dieterich D, Bacon BR, Flamm SL. et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014; 60: 220a-220a
339 Jensen DM, O’Leary JG, Pockros PJ. et al. Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort. Hepatology 2014; 60: 219a-220a
340 Kwo P, Gitlin N, Nahass R. et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 2016; 64: 370-380
341 Gane EJ, Stedman CA, Hyland RH. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. The New England journal of medicine 2013; 368: 34-44
342 Osinusi A, Meissner EG, Lee YJ. et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. Jama 2013; 310: 804-811
343 Lalezari JP, Nelson DR, Hyland RH. et al. Once Daily Sofosbuvir Plus Ribavirin for 12 and 24 Weeks in Treatment-Naive Patients with Hcv Infection: The Quantum Study. Journal of hepatology 2013; 58: S346-S346
344 Foster GR, Afdhal N, Roberts SK. et al. Sofosbuvir and Velpatasvir for HCV-Genotype 2 and 3 Infection. The New England journal of medicine 2015; 373: 2608-2617
345 Lawitz E, Mangia A, Wyles D. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. The New England journal of medicine 2013; 368: 1878-1887
346 Jacobson IM, Gordon SC, Kowdley KV. et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. The New England journal of medicine 2013; 368: 1867-1877
347 Zeuzem S, Dusheiko GM, Salupere R. et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. The New England journal of medicine 2014; 370: 1993-2001
348 Susser S, Dietz J, Barak M. et al. Prevalence and Clinical Importance of Hepatitis C Virus Genotype 2 K/1b Chimeras. Journal of hepatology 2016; 64: S136-S136
349 Hezode C, Reau N, Svarovskaia E. et al. Resistance Analysis in 1284 Patients with Genotype 1 to 6 Hcv Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Astral-1, Astral-2, Astral-3 and Astral-4 Studies. Journal of hepatology 2016; 64: S399-S400
350 Curry MP, O’Leary JG, Bzowej N. et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. The New England journal of medicine 2015; 373: 2618-2628
351 Nelson DR, Cooper JN, Lalezari JP. et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127-1135
352 Leroy V, Angus P, Bronowicki JP. et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 2016; 63: 1430-1441
353 Link JO, Taylor JG, Xu L. et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. Journal of medicinal chemistry 2014; 57: 2033-2046
354 Cheng G, Peng B, Corsa A. et al. Antiviral Activity and Resistance Profile of the Novel Hcv Ns5a Inhibitor Gs-5885. Journal of hepatology 2012; 56: S464-S464
355 Gane EJ, Hyland RH, An D. et al. High Efficacy of LDV/SOF Regimens for 12 Weeks for Patients with HCV-Genotype 3 or 6 Infection. Hepatology 2014; 60: 1274a-1275a
356 Susser S, Dietz J, Vermehren J. et al. European Ravs Database: Frequency and Characteristics of Ravs in Treatment-Naive and Daa-Experienced Patients. Journal of hepatology 2016; 64: S139-S139
357 Kohli A, Kapoor R, Sims Z. et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. The Lancet Infectious diseases 2015; 15: 1049-1054
358 Abergel A, Metivier S, Samuel D. et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 2016; 64: 1049-1056
359 Rockstroh JK, Nelson M, Katlama C. et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. The lancet HIV 2015; 2: e319-e327
360 Hezode C, Asselah T, Reddy KR. et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet (London, England) 2015; 385: 2502-2509
361 Asselah T, Hezode C, Qaqish RB. et al. High Svr Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis with Ombitasvir/Paritaprevir/Ritonavir Co-Administered with Ribavirin (Agate-I). Journal of hepatology 2016; 64: S827-S827
362 Waked I, Shiha G, Qaqish RB. et al. Ombitasvir/Paritaprevir/Ritonavir with Ribavirin Achieves High Sustained Virologic Response (Svr) Rates in Egyptian Adults with Chronic Hcv Genotype 4 Infection (Agate-Ii). Journal of hepatology 2016; 64: S772-S772
363 Moreno C, Hezode C, Marcellin P. et al. Once-Daily Simeprevir (Tmc435) with Peginterferon/Ribavirin in Treatment-Naive or Treatment-Experienced Chronic Hcv Genotype 4-Infected Patients: Final Results of a Phase Iii Trial. Journal of hepatology 2014; 60: S535-S535
364 Lenz O, Vijgen L, Berke JM. et al. Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 2013; 58: 445-451
365 El Raziky M, Gamil M, Hammad R. et al. Treatment of Hepatitis C Genotype 4 patients with Simeprevir and Sofosbuvir: Preliminary Results from a Phase IIa, Partially Randomised, Open-label Trial conducted in Egypt (OSIRIS). Hepatology 2015; 62: 784a-784a
366 Abergel A, Asselah T, Metivier S. et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. The Lancet Infectious diseases 2016; 16: 459-464
367 Gane EJ, Hyland RH, An D. et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015; 149: 1454-1461 e1451
368 Poordad F, Nelson DA, Feld JJ. Pooled safety assessment of ombitasvir/paritaprevir/ritonavir +/- dasbuvir +/- ribvairin in HCV infected patients with Child-Pugh A compensated cirrhosis. Optimize Workshop 2016; 12th April 2016. Barcelona:
369 Padegimas A, Forde KA, Goldberg LR. et al. Myo-pericarditis secondary to ledipasvir-sofosbuvir therapy. J Hepatol 2016; 64: 1196-1198
370 Marchan-Lopez A, Dominguez-Dominguez L, Kessler-Saiz P. et al. Liver failure in human immunodeficiency virus – Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy. J Hepatol 2016; 64: 752-753
371 Welker MW, Luhne S, Lange CM. et al. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol 2016; 64: 790-799
372 Hoofnagle JH. Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. J Hepatol 2016; 64: 763-765
373 Charlton M, Gane E, Manns MP. et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-117
374 Bourliere M, Bronowicki JP, de Ledinghen V. et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). The Lancet Infectious diseases 2015; 15: 397-404
375 Hezode C, Chevaliez S, Scoazec G. et al. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology 2016; 63: 1809-1816
376 Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2016; 64: 486-504
377 Lenz O, Verbinnen T, Fevery B. et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol 2015; 62: 1008-1014
378 Krishnan P, Beyer J, Mistry N. et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrobial agents and chemotherapy 2015; 59: 979-987
379 Krishnan P, Tripathi R, Schnell G. et al. Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials. Hepatology 2014; 60: 1134a-1135a
380 Svarovskaia ES, Gane E, Dvory-Sobol H. et al. L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. The Journal of infectious diseases 2016; 213: 1240-1247
381 Svarovskaia ES, Dvory-Sobol H, Parkin N. et al. Infrequent development of resistance in genotype 1–6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014; 59: 1666-1674
382 Hedskog C, Dvory-Sobol H, Gontcharova V. et al. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. Journal of viral hepatitis 2015; 22: 871-881
383 Krishnan P, Tripathi R, Schnell G. et al. Long-Term Follow-up of Treatment-Emergent Resistance-Associated Variants in Ns3, Ns5a and Ns5b with Paritaprevir/R-, Ombitasvir- and Dasabuvir-Based Regimens. Journal of hepatology 2015; 62: S220-S220
384 Lawitz E, Flamm S, Yang JC. et al. Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir- Based Regimens with Ledipasvir/Sofosbuvir for 24 Weeks. Journal of hepatology 2015; 62: S192-S192
385 Wyles D, Pockros P, Morelli G. et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 2015; 61: 1793-1797
386 Vermehren J, Susser S, Dietz J. et al. Retreatment of Patients Who Failed Daa-Combination Therapies: Real-World Experience from a Large Hepatitis C Resistance Database. Journal of hepatology 2016; 64: S188-S188
387 Wilson EM, Kattakuzhy S, Sidharthan S. et al. Successful Retreatment of Chronic HCV-Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; 62: 280-288
388 Gane E, Nahass R, Luketic V. et al. Efficacy of 12 or 18 Weeks of Grazoprevir Plus Elbasvir with Ribavirin in Treatment-Naive, Noncirrhotic Hcv Genotype 3-Infected Patients. Journal of hepatology 2015; 62: S621-S621
389 Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology 2016; 151: 70-86
390 Poordad F, Bennett M, Sepe TE. et al. Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with Hcv Genotype 1-Infection Who Failed a Prior Course of Daa Therapy: The Quartz-I Study. Journal of hepatology 2016; 64: S767-S768
391 Lawitz E, Kowdley K, Curry M. et al. High Efficacy of Sofosbuvir/Velpatasvir Plus Gs-9857 for 12 Weeks in Treatment-Experienced Genotype 1–6 Hcv-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals. Journal of hepatology 2016; 64: S139-S140
392 Lawitz EJ, Poordad F, Gutierrez J. et al. C-Swift Retreatment Final Results: Highly Successful Retreatment of Gt1-Infected Patients with 12 Weeks of Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin after Failure of Short-Duration All-Oral Therapy. Journal of hepatology 2016; 64: S763-S763
393 Poordad F, Gordon SC, Asatryan A. et al. High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients Who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study. Journal of hepatology 2016; 64: S160-S161
394 Jacobson IM, Dore GJ, Foster GR. et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet (London, England) 2014; 384: 403-413
395 Manns M, Marcellin P, Poordad F. et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England) 2014; 384: 414-426
396 Manns M, Pol S, Jacobson IM. et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet (London, England) 2014; 384: 1597-1605
397 Sarrazin C, Dvory-Sobol H, Svarovskaia ES. et al. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. Gastroenterology 2016; 151: 501-512 e501
398 Sarrazin C, Dvory-Sobol H, Svarovskaia ES. et al. The Prevalence and the Effect of Hcv Ns5a Resistance Associated Variants in Subjects with Compensated Cirrhosis Treated with Ledipasvir/Sofosbuvir Plus /- Rbv. Journal of hepatology 2015; 62: S620-S620
399 Sarrazin C, Sulkowski MS, Krishnan P. et al. Effect of Baseline Resistance-Associated Variants on Svr with the 3d Regimen with and without Rbv in Gt1a and Gt1b-Infected Patients. Journal of hepatology 2016; 64: S214-S214
400 Dietz J, Susser S, Berkowski C. et al. Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. PloS one 2015; 10: e0134395
401 Sarrazin C, Dvory-Sobol H, Svarovskaia ES. et al. Baseline and Post-baseline Resistance Analyses of Phase 2/3 Studies of Ledipasvir/Sofosbuvir +/- RBV. Hepatology 2014; 60: 1128a-1128a
402 Sullivan JC, De Meyer S, Bartels DJ. et al. Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials. Journal of hepatology 2011; 54: S4-S4
403 Reddy KR, Pol S, Thuluvath PJ. et al. Long-term follow-up of patients treated with daclatasvir-based regimens in phase 2 and 3 studies. Hepatology 2014; 60: 1154a-1155a
404 Howe AY, Long JM, Thompson S. et al. Analysis of the Durability of Response and Persistance of Resistance Associated Variants during Long Term Follow Up after Boceprevir plus Pegylated Interferon/Ribavirin Therapy-3 Year Analysis. Hepatology 2013; 58: 1095a-1095a
405 Desnoyer A, Pospai D, Le MP. et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 2016; 65: 40-47
406 Bhamidimarri KR, Czul F, Peyton A. et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol 2015; 63: 763-765
407 Saxena V, Koraishy FM, Sise ME. et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver international : official journal of the International Association for the Study of the Liver 2016; 36: 807-816
408 Perumpail RB, Wong RJ, Pham EA. et al. A New Standard of Care? Standard Dose Sofosbuvir in an HCV-Infected Liver Transplant Recipient Undergoing Hemodialysis . Digestive diseases and sciences 2016; 61: 39-41
409 Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min. Liver international : official journal of the International Association for the Study of the Liver 2016; 36: 798-801
410 Singh T, Guirguis J, Anthony S. et al. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series. Liver international : official journal of the International Association for the Study of the Liver 2016; 36: 802-806
411 Hezode C, Hirschfield GM, Ghesquiere W. et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2015; 64: 948-956
412 Renet S, Chaumais MC, Antonini T. et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 2015; 149: 1378-1380 e1371
413 Fontaine H, Lazarus A, Pol S. et al. Bradyarrhythmias Associated with Sofosbuvir Treatment. The New England journal of medicine 2015; 373: 1886-1888
414 Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology 2015; 149: 1315-1317
415 Gane EJ, Robson RA, Bonacini M. et al. Safety, Anti-Viral Efficacy and Pharmacokinetics (PK) of Sofosbuvir (SOF) in Patients with Severe Renal Impairment. Hepatology 2014; 60: 667a-667a
416 Roth D, Nelson DR, Bruchfeld A. et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet (London, England) 2015; 386: 1537-1545
417 Dore GJ, Conway B, Luo Y. et al. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. J Hepatol 2016; 64: 19-28
418 Pockros PJ, Reddy KR, Mantry PS. et al. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology 2016; 150: 1590-1598
419 Terrault N, Zeuzem S, Di Bisceglie AM. et al. Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study. Hepatology 2015; 62: 256a-256a
420 DeVreese L, Giguere P, Corsi D. et al. Influence of Proton Pump Inhibitors and H2 Receptor Antagonists on Direct Acting Antiviral Hcv Sustained Virologic Response. Journal of hepatology 2016; 64: S790-S790
421 Afdhal N, Bacon B, Curry M. et al. No Effect of Proton Pump Inhibitor (Ppi) Use on Svr with Ledipasvir/Sofosbuvir (Ldv/Sof): Realworld Data from 2034 Genotype 1 Patients in the Trio Network. Journal of hepatology 2016; 64: S222-S222
422 Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012; 55: 1048-1057
423 Sarrazin C, Svarovskaia ES, Martin R. HCV reinfection cases in phase 3 studies of sofosbuvir. Journal of hepatology 2015; 62: S222
424 Forman LM, Lewis JD, Berlin JA. et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896
425 Wiesner R, Edwards E, Freeman R. et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96
426 Freeman RB. MELD: the holy grail of organ allocation?. J Hepatol 2005; 42: 16-20
427 Mazzaferro V, Chun YS, Poon RT. et al. Liver transplantation for hepatocellular carcinoma. Annals of surgical oncology 2008; 15: 1001-1007
428 Mazzaferro V, Regalia E, Doci R. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. The New England journal of medicine 1996; 334: 693-699
429 Cholongitas E, Marelli L, Shusang V. et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2006; 12: 1049-1061
430 Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol 2011; 54: 1297-1306
431 D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231
432 Yao FY, Xiao L, Bass NM. et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2007; 7: 2587-2596
433 Yao FY, Ferrell L, Bass NM. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403
434 Decaens T, Roudot-Thoraval F, Hadni-Bresson S. et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2006; 12: 1761-1769
435 Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Annals of surgery 2004; 240: 451-459 discussion 459–461
436 Saab S, Niho H, Comulada S. et al. Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. Liver international: official journal of the International Association for the Study of the Liver 2005; 25: 940-945
437 Berenguer M, Ferrell L, Watson J. et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-684
438 Berenguer M, Prieto M, Palau A. et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2003; 9: 228-235
439 Berenguer M, Prieto M, Rayon JM. et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-858
440 Neff GW, O’Brien CB, Nery J. et al. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2004; 10: 1497-1503
441 Roayaie S, Schiano TD, Thung SN. et al. Results of retransplantation for recurrent hepatitis C. Hepatology 2003; 38: 1428-1436
442 Rosen HR, Prieto M, Casanovas-Taltavull T. et al. Validation and refinement of survival models for liver retransplantation. Hepatology 2003; 38: 460-469
443 Yoo HY, Maheshwari A, Thuluvath PJ. Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2003; 9: 897-904
444 Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998; 66: 1612-1616
445 Pelletier SJ, Schaubel DE, Punch JD. et al. Hepatitis C is a risk factor for death after liver retransplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2005; 11: 434-440
446 Ghabril M, Dickson R, Wiesner R. Improving outcomes of liver retransplantation: an analysis of trends and the impact of Hepatitis C infection. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008; 8: 404-411
447 Bahra M, Neumann UP, Jacob D. et al. Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C. Transplant international : official journal of the European Society for Organ Transplantation 2007; 20: 771-778
448 McCashland T, Watt K, Lyden E. et al. Retransplantation for hepatitis C: results of a U. S. multicenter retransplant study. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2007; 13: 1246-1253
449 Ghabril M, Dickson RC, Machicao VI. et al. Liver retransplantation of patients with hepatitis C infection is associated with acceptable patient and graft survival. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2007; 13: 1717-1727
450 Jain A, Orloff M, Abt P. et al. Survival outcome after hepatic retransplantation for hepatitis C virus-positive and -negative recipients. Transplantation proceedings 2005; 37: 3159-3161
451 Charlton M. Natural history of hepatitis C and outcomes following liver transplantation. Clinics in liver disease 2003; 7: 585-602
452 Ghobrial RM. Retransplantation for recurrent hepatitis C. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2002; 8: S38-S43
453 McCashland TM. Retransplantation for recurrent hepatitis C: positive aspects. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2003; 9: S67-S72
454 Rosen HR. Retransplantation for hepatitis C: implications of different policies. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2000; 6: S41-S46
455 Watt KD, Lyden ER, McCashland TM. Poor survival after liver retransplantation: is hepatitis C to blame?. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2003; 9: 1019-1024
456 Carmiel-Haggai M, Fiel MI, Gaddipati HC. et al. Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2005; 11: 1567-1573
457 Rosen HR. Liver retransplantation for hepatitis C: seeing is believing. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2007; 13: 1217-1218
458 Thomas RM, Brems JJ, Guzman-Hartman G. et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2003; 9: 905-915
459 Picciotto FP, Tritto G, Lanza AG. et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-465
460 Ferenci P, Kozbial K, Mandorfer M. et al. HCV targeting of patients with cirrhosis. J Hepatol 2015; 63: 1015-1022
461 Ruiz I, Feray C, Pawlotsky JM. et al. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2015; 21: 408-409
462 NCT02350569. Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting. ClinicalTrialsgovNCT02485080 Online unter ClinicalTrialsgov
463 Poordad F, Schiff E, Vierling JM. et al. Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients with Advanced Cirrhosis or Post-transplant Recurrence: Final Results of the ALLY-1 Study. American Journal of Gastroenterology 2016; 111: S346-S346
464 Terrault NSR, Stapathy SK, O’Leary JG. et al. Novel Approach for the Prevention of Recurrent Hepatitis C in Liver Transplant Recipients: Preliminary Results from Ongoing Phase III Trial with Civacir. EASL Late-Breaking Poster 17 2015 2015
465 Foster GR, Afdhal N, Roberts SK. et al. Sofosbuvir and Velpatasvir for HCV-Genotype 2 and 3 Infection. The New England journal of medicine 2015; 373: 2608-2617
466 Feld JJ, Jacobson IM, Hezode C. et al. Sofosbuvir and Velpatasvir for HCV-Genotype 1, 2, 4, 5, and 6 Infection. The New England journal of medicine 2015; 373: 2599-2607
467 Afdhal NEG, Calleja JL, McCaughan G. et al. Sofosbuvir and ribavirin for the treatment of chronic HCW with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J Hepatol 2014; S28
468 Hezode CdLV, Fontaine H, Zoulim F. et al. Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program. Hepatology 2015; 314A
469 Lawitz E, Makara M, Akarca US. et al. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. Gastroenterology 2015; 149: 971-980.e971
470 Muir AJ, Poordad F, Lalezari J. et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. Jama 2015; 313: 1736-1744
471 Reddy KR, Bourliere M, Sulkowski M. et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology 2015; 62: 79-86
472 Welzel TM, Petersen J, Ferenci P. et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: Interim results of a multicenter European compassionate use program. Hepatology 2015; 62: 225a-226a
473 Ferenci P, Bernstein D, Lalezari J. et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. The New England journal of medicine 2014; 370: 1983-1992
474 Afdhal NEG, Calleja J, McCaughan G. et al. Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. J Hepatol 2015; S269-S270
475 Lens S, Rincon D, Garcia-Retortillo M. et al. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2015; 13: 1846-1853.e1841
476 Saxena V, Nyberg L, Pauly M. et al. Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis. Hepatology 2015; 62: 715-725
477 [Anonym]. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney international Supplement 2008; 81: S1-S99 . DOI: 10.1038/ki.2008
478 Ingsathit A, Kamanamool N, Thakkinstian A. et al. Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: a systematic review and meta-analysis. Transplantation 2013; 95: 943-948
479 Ridruejo E, Cusumano A, Diaz C. et al. Hepatitis C virus infection and outcome of renal transplantation. Transplantation proceedings 2007; 39: 3127-3130
480 Pockros PJ, Reddy KR, Mantry PS. et al. Efficacy of Direct-acting Antiviral Combination for Patients with HCV-Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology 2016;
481 Nazario HE, Ndungu M, Modi AA. Sofosbuvir and Simeprevir in Hepatitis C genotype 1- patients with End-Stage Renal Disease on hemodialysis or GFR <30mL/min. Liver international : official journal of the International Association for the Study of the Liver 2015;
482 Englum BR, Ganapathi AM, Speicher PJ. et al. Impact of donor and recipient hepatitis C status in lung transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2016; 35: 228-235
483 Gasink LB, Blumberg EA, Localio AR. et al. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. Jama 2006; 296: 1843-1850
484 Kim EY, Ko HH, Yoshida EM. A concise review of hepatitis C in heart and lung transplantation. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2011; 25: 445-448
485 Manns M, Forns X, Samuel D. et al. Ledipasvir/Sofosbuvir with Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients with Hcv Infection: Preliminary Results of the Prospective Solar 2 Trial. Transplant Int 2015; 28: 21-21
486 Kwo PY, Mantry PS, Coakley E. et al. An interferon-free antiviral regimen for HCV after liver transplantation. The New England journal of medicine 2014; 371: 2375-2382
487 Coilly AFC, De Ledinghen V. et al. The Association of Sofosbuvir and Daclatasvir for Treating Severe Recurrence of Hcv Infection after Liver Transplantation: Results from a Large French Prospective Multicentric Anrs Co23 Cupilt Cohort. J Hepatol 2015; 62: S236-S237
488 Pungpapong S, Aqel B, Leise M. et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880-1886
489 Ellingson K, Seem D, Nowicki M. et al. Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2011; 11: 1201-1208
490 Marroquin CE, Marino G, Kuo PC. et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2001; 7: 762-768
491 Alvaro E, Abradelo M, Fuertes A. et al. Liver transplantation from anti-hepatitis C virus-positive donors: our experience. Transplantation proceedings 2012; 44: 1475-1478
492 Velidedeoglu E, Desai NM, Campos L. et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 2002; 73: 582-587
493 Burr AT, Li Y, Tseng JF. et al. Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World journal of surgery 2011; 35: 1590-1595
494 Northup PG, Argo CK, Nguyen DT. et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transplant international : official journal of the European Society for Organ Transplantation 2010; 23: 1038-1044
495 Lai JC, O’Leary JG, Trotter JF. et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2012; 18: 532-538
496 Terrault NA, Roland ME, Schiano T. et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2012; 18: 716-726
497 Patwardhan VR, Curry MP. Reappraisal of the hepatitis C virus-positive donor in solid organ transplantation. Current opinion in organ transplantation 2015; 20: 267-275
498 Kucirka LM, Alexander C, Namuyinga R. et al. Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009; 9: 620-628
499 Mehra MR, Canter CE, Hannan MM. et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2016; 35: 1-23
500 Torres HA, Chong PP, De Lima M. et al. Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015; 21: 1870-1882
501 Kucirka LM, Peters TG, Segev DL. Impact of donor hepatitis C virus infection status on death and need for liver transplant in hepatitis C virus-positive kidney transplant recipients. American journal of kidney diseases : the official journal of the National Kidney Foundation 2012; 60: 112-120
502 Locasciulli A, Testa M, Valsecchi MG. et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 1999; 68: 1486-1491
503 Varma A, Saliba RM, Torres HA. et al. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone marrow transplantation 2016;
504 Kyvernitakis A, Mahale P, Popat UR. et al. Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2016; 22: 717-722
505 Nakasone H, Kurosawa S, Yakushijin K. et al. Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation. American journal of hematology 2013; 88: 477-484
506 Tomblyn M, Chen M, Kukreja M. et al. No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation. Transplant infectious disease : an official journal of the Transplantation Society 2012; 14: 468-478
507 Ljungman P, Locasciulli A, de Soria VG. et al. Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy. Bone marrow transplantation 2012; 47: 1217-1221
508 Peffault de Latour R, Ribaud P, Robin M. et al. Allogeneic hematopoietic cell transplant in HCV-infected patients. J Hepatol 2008; 48: 1008-1017
509 Arai Y, Kanda J, Nakasone H. et al. Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation. Bone marrow transplantation 2016; 51: 96-102
510 Ramos CA, Saliba RM, de Padua L. et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 2009; 94: 249-257
511 Evans AT, Loeb KR, Shulman HM. et al. Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases. The American journal of surgical pathology 2015; 39: 212-220
512 Fischler B, Priftakis P, Sundin M. Sofosbuvir and Simeprevir Treatment of a Stem Cell Transplanted Teenager with Chronic Hepatitis C Infection. The Pediatric infectious disease journal 2016;
513 Thomas P, Santiago T, Dallas MH. Treatment of hepatitis C in a pediatric patient using simeprevir and sofosbuvir immediately after an umbilical cord blood transplantation. Bone marrow transplantation 2016;
514 Pinana JL, Serra MA, Hernandez-Boluda JC. et al. Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant. Transplant infectious disease : an official journal of the Transplantation Society 2016; 18: 89-92
515 [Anonym]. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone marrow transplantation 2009; 44: 453-558
516 Ferreira-Gonzalez A, Shiffman ML. Use of diagnostic testing for managing hepatitis C virus infection. Seminars in liver disease 2004; 24 (Suppl. 02) 9-18
517 Laperche S, Bouchardeau F, Andre-Garnier E. et al. Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits. Journal of clinical microbiology 2011; 49: 1113-1115
518 Shuhart MC, Myerson D, Childs BH. et al. Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood 1994; 84: 3229-3235
519 Curry MP, Forns X, Chung RT. et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-107.e101
520 Yu TM, Lin CC, Shu KH. et al. Increased risk of hepatic complications in kidney transplantation with chronic virus hepatitis infection: A nationwide population-based cohort study. Scientific reports 2016; 6: 21312
521 Abbas MH, Ismail MI, El DeebSA. et al. Effect of pretransplant hepatitis C virus on the development of new-onset diabetes mellitus after transplant in Egyptian living-donor renal allotransplant recipients at Mansoura Urology and Nephrology Center. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2015; 13: 26-34
522 Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation. Nature reviews Nephrology 2015; 11: 172-182
523 Fabrizi F, Martin P, Dixit V. et al. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. Journal of viral hepatitis 2014; 21: 314-324
524 Burra P, Rodriguez-Castro KI, Marchini F. et al. Hepatitis C virus infection in end-stage renal disease and kidney transplantation. Transplant international : official journal of the European Society for Organ Transplantation 2014; 27: 877-891
525 Singh N, Neidlinger N, Djamali A. et al. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clinical transplantation 2012; 26: 684-693
526 Corouge M, Vallet-Pichard A, Pol S. HCV and the kidney. Liver international : official journal of the International Association for the Study of the Liver 2016; 36 (Suppl. 01) 28-33
527 Sawinski D, Kaur N, Ajeti A. et al. Successful treatment of Hepatitis C in renal transplant recipients with direct-acting antiviral agents. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015;
528 Kamar N, Marion O, Rostaing L. et al. Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015;
529 Suarez-Benjumea A, Gonzalez-Corvillo C, Bernal-Blanco G. et al. New Antivirals for Hepatitis C Infection Among Infected Kidney Transplant Recipients: A Case Report. Transplantation proceedings 2015; 47: 2672-2674
530 Doucette KE, Halloran K, Kapasi A. et al. Outcomes of Lung Transplantation in Recipients with Hepatitis C Virus Infection. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2016;
531 Fong TL, Cho YW, Hou L. et al. Outcomes after lung transplantation and practices of lung transplant programs in the United States regarding hepatitis C seropositive recipients. Transplantation 2011; 91: 1293-1296
532 Lee I, Localio R, Brensinger CM. et al. Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2011; 30: 1266-1274
533 Trakroo S, Qureshi K. Successful Treatment of Chronic Hepatitis C Infection With Direct-Acting Antivirals in a Heart Transplant Recipient: A Case Report. Transplantation proceedings 2015; 47: 2295-2297
534 Burgess S, Partovi N, Yoshida EM. et al. Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients. The Annals of pharmacotherapy 2015; 49: 674-687
535 [Anonym]. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236
536 Kwo PY, Badshah MB. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Current opinion in organ transplantation 2015; 20: 235-241
537 Rodriguez M, Navascues CA, Martinez A. et al. Hepatitis C virus infection in patients with acute hepatitis B. Infection 1992; 20: 316-319
538 Liaw YF, Chu CM, Chang-Chien CS. et al. Simultaneous acute infections with hepatitis non-A, non-B, and B viruses. Digestive diseases and sciences 1982; 27: 762-764
539 Feray C, Gigou M, Samuel D. et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993; 104: 549-555
540 Mimms LT, Mosley JW, Hollinger FB. et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. Bmj 1993; 307: 1095-1097
541 Alberti A, Pontisso P, Chemello L. et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol 1995; 22: 38-41
542 Yan BM, Lee SS. Acute coinfection with hepatitis B and hepatitis C viruses. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2005; 19: 729-730
543 Coppola N, Marrocco C, Di Caprio D. et al. Acute hepatitis B and C virus coinfection: a virological and clinical study of 3 cases. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003; 36: 528-532
544 Chu CM, Sheen IS, Liaw YF. The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. Gastroenterology 1994; 107: 189-195
545 Liaw YF. Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Journal of gastroenterology 2002; 37: 65-68
546 Wu JC, Chen CL, Hou MC. et al. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: application and limitations of the polymerase chain reaction. Hepatology 1994; 19: 836-840
547 Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut 1999; 45: 613-617
548 Sagnelli E, Coppola N, Messina V. et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36: 1285-1291
549 Liaw YF, Chen YC, Sheen IS. et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126: 1024-1029
550 Georgiadou SP, Zachou K, Rigopoulou E. et al. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. Journal of viral hepatitis 2004; 11: 358-365
551 Kannangai R, Vivekanandan P, Netski D. et al. Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2007; 39: 101-105
552 Cacciola I, Pollicino T, Squadrito G. et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. The New England journal of medicine 1999; 341: 22-26
553 Cardoso C, Alves AL, Augusto F. et al. Occult hepatitis B infection in Portuguese patients with chronic hepatitis C liver disease: prevalence and clinical significance. European journal of gastroenterology & hepatology 2013; 25: 142-146
554 Fong TL, Di Bisceglie AM, Waggoner JG. et al. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991; 14: 64-67
555 Zarski JP, Bohn B, Bastie A. et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 27-33
556 Sagnelli E, Pasquale G, Coppola N. et al. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 2004; 32: 144-148
557 Ilan Y, Ashur Y, Tur-Kaspa R. et al. Chronic hepatitis C virus infection with exposure to hepatitis B virus. Israel journal of medical sciences 1994; 30: 259-263
558 Mohamed AelS, al KarawiMA, Mesa GA. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepato-gastroenterology 1997; 44: 1404-1406
559 Chen YC, Sheen IS, Chu CM. et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 1084-1089
560 Colombari R, Dhillon AP, Piazzola E. et al. Chronic hepatitis in multiple virus infection: histopathological evaluation. Histopathology 1993; 22: 319-325
561 Villari D, Pernice M, Spinella S. et al. Chronic hepatitis in patients with active hepatitis B virus and hepatitis C virus combined infections: a histological study. The American journal of gastroenterology 1995; 90: 955-958
562 Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. International journal of cancer 1998; 75: 347-354
563 Shi J, Zhu L, Liu S. et al. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. British journal of cancer 2005; 92: 607-612
564 Cho LY, Yang JJ, Ko KP. et al. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. International journal of cancer 2011; 128: 176-184
565 Benvegnu L, Fattovich G, Noventa F. et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74: 2442-2448
566 Chiaramonte M, Stroffolini T, Vian A. et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85: 2132-2137
567 Eyster ME, Diamondstone LS, Lien JM. et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. Journal of acquired immune deficiency syndromes 1993; 6: 602-610
568 Soto B, Sanchez-Quijano A, Rodrigo L. et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5
569 Sanchez-Quijano A, Andreu J, Gavilan F. et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1995; 14: 949-953
570 Darby SC, Ewart DW, Giangrande PL. et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C UK Haemophilia Centre Directors’ Organisation. Lancet (London, England) 1997; 350: 1425-1431
571 Poynard T, Mathurin P, Lai CL. et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38: 257-265
572 Chen TY, Ding EL, Seage IiiGR. et al. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009; 49: 1605-1615
573 Lo 3rd ReV, Kallan MJ. et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals of internal medicine 2014; 160: 369-379
574 Rockstroh JK, Spengler U, Sudhop T. et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. The American journal of gastroenterology 1996; 91: 2563-2568
575 Benhamou Y, Di Martino V, Bochet M. et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283-287
576 Qurishi N, Kreuzberg C, Luchters G. et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (London, England) 2003; 362: 1708-1713
577 Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M. et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46: 622-630
578 Martin-Carbonero L, Benhamou Y, Puoti M. et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004; 38: 128-133
579 de Ledinghen V, Barreiro P, Foucher J. et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. Journal of viral hepatitis 2008; 15: 427-433
580 Fierer DS, Dieterich DT, Fiel MI. et al. Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013; 56: 1038-1043
581 Kirk GD, Mehta SH, Astemborski J. et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Annals of internal medicine 2013; 158: 658-666
582 Zylberberg H, Pialoux G, Carnot F. et al. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998; 27: 1255-1258
583 Perez-Olmeda M, Garcia-Samaniego J, Soriano V. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. Aids 2000; 14: 212
584 Chung RT, Evans SR, Yang Y. et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. Aids 2002; 16: 1915-1923
585 Fialaire P, Payan C, Vitour D. et al. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. The Journal of infectious diseases 1999; 180: 574-575
586 Berenguer J, Alvarez-Pellicer J, Martin PM. et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-413
587 Limketkai BN, Mehta SH, Sutcliffe CG. et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. Jama 2012; 308: 370-378
588 Mira JA, Rivero-Juarez A, Lopez-Cortes LF. et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013; 56: 1646-1653
589 Mehta SD, Ghanem KG, Rompalo AM. et al. HIV seroconversion among public sexually transmitted disease clinic patients: analysis of risks to facilitate early identification. Journal of acquired immune deficiency syndromes 2006; 42: 116-122
590 Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annual review of medicine 2008; 59: 473-485
591 Ghosn J, Pierre-Francois S, Thibault V. et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV medicine 2004; 5: 303-306
592 Luetkemeyer A, Hare CB, Stansell J. et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. Journal of acquired immune deficiency syndromes 2006; 41: 31-36
593 Danta M, Brown D, Bhagani S. et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. Aids 2007; 21: 983-991
594 van de Laar TJ, Matthews GV, Prins M. et al. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. Aids 2010; 24: 1799-1812
595 Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. Journal of viral hepatitis 2006; 13: 34-41
596 Thomas DL, Astemborski J, Rai RM. et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. Jama 2000; 284: 450-456
597 Dominguez S, Ghosn J, Valantin MA. et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. Aids 2006; 20: 1157-1161
598 Macias J, Berenguer J, Japon MA. et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50: 1056-1063
599 Konerman MA, Mehta SH, Sutcliffe CG. et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 2014; 59: 767-775
600 Basu P, Shah NJ, John N. et al. Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir combination therapy in the management of acute hepatitis C: A randomized open label prospective clinical pilot study. SLAM C study. Interim data. Hepatology 2015; 62: 736a-736a
601 Martinello M, Gane EJ, Hellard M. et al. Sofosbuvir and Ribavirin for Six Weeks Is Not Effective Among People with Acute and Recently Acquired HCV Infection: The DARE-C II Study. Hepatology 2015; 62: 741a-742a
602 Fierer DS, Barbati Z, Dieterich D. et al. Sofosbuvir in the Treatment of Acute HCV Infection in HIV-infected Men. Hepatology 2015; 62: 745a-746a
603 Naggie S, Marks KM, Hughes M. et al. Sofosbuvir Plus Ribavirin Without Interferon For Treatment of Acute Hepatitis C Virus Infection in HIV-1 infected Individuals (SWIFT-C). Hepatology 2015; 62: 748a-748a
604 Sarrazin C, Berg T, Ross RS. et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Zeitschrift fur Gastroenterologie 2010; 48: 289-351
605 Potthoff A, Wedemeyer H, Boecher WO. et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008; 49: 688-694
606 Yu ML, Lee CM, Chen CL. et al. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology 2013; 57: 2135-2142
607 Wahle RC, Perez RM, Pereira PF. et al. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2015; 19: 533-537
608 Collins JM, Raphael KL, Terry C. et al. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015; 61: 1304-1306
609 Ende AR, Kim NH, Yeh MM. et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. Journal of medical case reports 2015; 9: 164
610 Coppola N, Stanzione M, Messina V. et al. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. Journal of viral hepatitis 2012; 19: 890-896
611 European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370-398
612 Pockros PJ. Black Box Warning for Possible HBV Reactivation During DAA Therapy for Chronic HCV Infection. Gastroenterology & hepatology 2017; 13: 536-540
613 Mathurin P, Thibault V, Kadidja K. et al. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. Journal of viral hepatitis 2000; 7: 15-22
614 Brotman B, Prince AM, Huima T. et al. Interference between non-A, non-B and hepatitis B virus infection in chimpanzees. Journal of medical virology 1983; 11: 191-205
615 Sagnelli E, Coppola N, Scolastico C. et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32: 1106-1110
616 Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995; 22: 1101-1108
617 Eyster ME, Sanders JC, Battegay M. et al. Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C. Digestive diseases and sciences 1995; 40: 1583-1588
618 Jardi R, Rodriguez F, Buti M. et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001; 34: 404-410
619 Wedemeyer H, Tillmann HL, Tegtmeyer B. et al. Infection with multiple hepatitis viruses: Evidence for suppression of HCV replication by HDV and HBV. Hepatology 2001; 34: 223a-223a
620 Deterding K, Pothakamuri SV, Schlaphoff V. et al. Clearance of chronic HCV infection during acute delta hepatitis. Infection 2009; 37: 159-162
621 Liaw YF, Tsai SL, Sheen IS. et al. Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. The American journal of gastroenterology 1998; 93: 354-359
622 Weltman MD, Brotodihardjo A, Crewe EB. et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. Journal of viral hepatitis 1995; 2: 39-45
623 Crockett SD, Keeffe EB. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Annals of clinical microbiology and antimicrobials 2005; 4: 13
624 Alavian SM, Tabatabaei SV, Behnava B. et al. Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2012; 17: 967-974
625 Lamers MH, Kirgiz OO, Heidrich B. et al. Interferon-alpha for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antiviral therapy 2012; 17: 1029-1037
626 Boyd A, Miailhes P, Brichler S. et al. Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients. AIDS research and human retroviruses 2013; 29: 1535-1540
627 Chen GY, Su TH, Kao JH. Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir. Journal of the Formosan Medical Association = Taiwan yi zhi 2015; 114: 1140-1141
628 Heidrich B, Yurdaydin C, Kabacam G. et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014; 60: 87-97
629 Heller T, Rotman Y, Koh C. et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Alimentary pharmacology & therapeutics 2014; 40: 93-104
630 Osinusi A, Townsend K, Kottilil S. Drug-Drug Interactions in Patients Co-infected With HCV and HIV--Reply. Jama 2015; 314: 186-187
631 Naggie S, Cooper C, Saag M. et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. The New England journal of medicine 2015; 373: 705-713
632 Rockstroh JK, Puoti M, Rodriguez-Torres M. et al. Sofosbuvir and Ribavirin therapy for the Treatment of HIV/HCV coinfected patients with HCV GT1–4 Infection: The PHOTON-1 and-2 Trials. Hepatology 2014; 60: 295a-296a
633 Sulkowski MS, Naggie S, Lalezari J. et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. Jama 2014; 312: 353-361
634 Molina JM, Orkin C, Iser DM. et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet (London, England) 2015; 385: 1098-1106
635 Del Bello DP, Bichoupan K, Yalamanchili R. et al. Real-World Data on HIV positive Patients with HCV-Genotype 1,2 and 3 on Sofosbuvir- and Simeprevir-containing Regimens. Hepatology 2014; 60: 683a-683a
636 Sulkowski MS, Eron JJ, Wyles D. et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. Jama 2015; 313: 1223-1231
637 Kirby B, Mathias A, Rossi S. et al. No Clinically Significant Pharmacokinetic Drug Interactions between Sofosbuvir (GS-7977) and HIV Antiretrovirals Atripla (R), Rilpivirine, Darunavir/ritonavir, or Raltegravir in Healthy Volunteers. Hepatology 2012; 56: 1067a-1067a
638 German P, Garrison K, Pang PS. Drug-Drug Interactions Between Anti-HCV Regimen Ledipasvir/Sofosbuvir and Antiretrovirals. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA: 2015 Abstract 82:
639 Ragni MV, Belle SH, Im K. et al. Survival of human immunodeficiency virus-infected liver transplant recipients. The Journal of infectious diseases 2003; 188: 1412-1420
640 de Vera ME, Dvorchik I, Tom K. et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006; 6: 2983-2993
641 Schreibman I, Gaynor JJ, Jayaweera D. et al. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation 2007; 84: 697-705
642 Duclos-Vallee JC, Feray C, Sebagh M. et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-417
643 Anadol E, Beckebaum S, Radecke K. et al. Orthotopic liver transplantation in human-immunodeficiency-virus-positive patients in Germany. AIDS research and treatment 2012; 2012: 197501
644 Sawinski D, Goldberg DS, Blumberg E. et al. Beyond the NIH Multicenter HIV Transplant Trial Experience: Outcomes of HIV+ Liver Transplant Recipients Compared to HCV+ or HIV+/HCV+ Coinfected Recipients in the United States. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015; 61: 1054-1062
645 Terrault NA, Roland ME, Schiano T. et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2012; 18: 716-726
646 Miro JM, Montejo M, Castells L. et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012; 12: 1866-1876
647 Bhagat V, Foont JA, Schiff ER. et al. Spontaneous clearance of hepatitis C virus after liver transplantation in two patients coinfected with hepatitis C virus and human immunodeficiency virus. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2008; 14: 92-95
648 Antonini TM, Sebagh M, Roque-Afonso AM. et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2011; 11: 1686-1695
649 Leroy V, Dumortier J, Coilly A. et al. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2015; 13: 1993-2001 e1991–1992
650 Herzer K, Welzel TM, Ferenci P. et al. Daclatasvir in combination with sofosbuvir with or without ribavirin is safe and efficacious in liver transplant recipients with HCV recurrence: Interim results of a multicenter compassionate use program. Hepatology 2015; 62: 341a-341a
651 Antonini TM, Coilly A, Radenne S. et al. Efficacy of Sofosbuvir-Based Treatment Regimens in Hiv/Hcv Co-Infected Patients after Liver Transplantation: The Anrs Co23 Cupilt Study. Journal of hepatology 2015; 62: S635-S636
652 Forns X, Charlton M, Denning J. et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61: 1485-1494
653 Grant JL, Hawkins C, Brooks H. et al. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection. Aids 2016; 30: 93-98
654 Frassetto LA, Browne M, Cheng A. et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2007; 7: 2816-2820
655 Tricot L, Teicher E, Peytavin G. et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009; 9: 1946-1952
656 Gastaca M, Aguero F, Rimola A. et al. Liver retransplantation in HIV-infected patients: a prospective cohort study. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012; 12: 2465-2476
657 Miro JM, Stock P. Liver retransplantation in HIV-infected patients: A multicenter and multinational cohort study CROI: Conference on retroviruses and opportunistic infections. 2013 Abstract 141
658 Dickson-Spillmann M, Haug S, Uchtenhagen A. et al. Rates of HIV and Hepatitis Infections in Clients Entering Heroin-Assisted Treatment between 2003 and 2013 and Risk Factors for Hepatitis C Infection. European addiction research 2016; 22: 181-191
659 Falade-Nwulia O, Seaberg EC, Snider AE. et al. Incident Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Men Who Have Sex With Men From Pre-HAART to HAART Periods: A Cohort Study. Annals of internal medicine 2015; 163: 673-680
660 Hope VD, Harris R, McVeigh J. et al. Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 1992–2013. Journal of acquired immune deficiency syndromes 2016; 71: 331-337
661 [Anonym]. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2015. Epidemiologisches Bulletin 2015; 34: 327-362
662 Mena G, Garcia-Basteiro AL, Bayas JM. Hepatitis B and A vaccination in HIV-infected adults: A review. Human vaccines & immunotherapeutics 2015; 11: 2582-2598
663 Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. The American journal of medicine 2005; 118: 75S-83S
664 Collier AC, Corey L, Murphy VL. et al. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Annals of internal medicine 1988; 109: 101-105
665 Keet IP, van Doornum G, Safary A. et al. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. Aids 1992; 6: 509-510
666 Rey D, Krantz V, Partisani M. et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000; 18: 1161-1165
667 Tedaldi EM, Baker RK, Moorman AC. et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004; 38: 1478-1484
668 Geretti AM, Committee BIW, Brook G. et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV medicine 2008; 9: 795-848
669 Altfeld M, Rockstroh JK, Addo M. et al. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol 1998; 29: 306-309
670 Overton ET, Sungkanuparph S, Powderly WG. et al. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2005; 41: 1045-1048
671 Lopes VB, Hassing RJ, de Vries-Sluijs TE. et al. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine 2013; 31: 1040-1044
672 O’Bryan TA, Rini EA, Okulicz J. et al. HIV viraemia during hepatitis B vaccination shortens the duration of protective antibody levels. HIV medicine 2015; 16: 161-167
673 Fuster F, Vargas JI, Jensen D. et al. CD4 / CD8 ratio as a predictor of the response to HBV vaccination in HIV-positive patients: A prospective cohort study. Vaccine 2016; 34: 1889-1895
674 Fonseca MO, Pang LW, de Paula CavalheiroN. et al. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23: 2902-2908
675 Cornejo-Juarez P, Volkow-Fernandez P, Escobedo-Lopez K. et al. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS research and therapy 2006; 3: 9
676 Cruciani M, Mengoli C, Serpelloni G. et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009; 27: 17-22
677 Potsch DV, Camacho LA, Tuboi S. et al. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine 2012; 30: 5973-5977
678 Whitaker JA, Rouphael NG, Edupuganti S. et al. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. The Lancet Infectious diseases 2012; 12: 966-976
679 Launay O, van der Vliet D, Rosenberg AR. et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. Jama 2011; 305: 1432-1440
680 Bunupuradah T, Ananworanich J, Pancharoen C. et al. Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression. Vaccine 2011; 29: 2962-2967
681 Shouval D, Roggendorf H, Roggendorf M. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Medical microbiology and immunology 2015; 204: 57-68
682 Piroth L, Launay O, Michel ML. et al. Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study. The Journal of infectious diseases 2016; 213: 1735-1742
683 Schreier E, Höhne M. Hepatitis C – Epidemiologie und Prävention. Bundesgesundheitsblatt 2001; 44: 7
684 Gerner P, Wirth S, Wintermeyer P. et al. Prevalence of hepatitis C virus infection in children admitted to an urban hospital. The Journal of infection 2006; 52: 305-308
685 Bortolotti F, Iorio R, Resti M. et al. Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. J Hepatol 2007; 46: 783-790
686 England K, Thorne C, Newell ML. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. The Lancet Infectious diseases 2006; 6: 83-90
687 Davison SM, Mieli-Vergani G, Sira J. et al. Perinatal hepatitis C virus infection: diagnosis and management. Archives of disease in childhood 2006; 91: 781-785
688 Polywka S, Schroter M, Feucht HH. et al. Low risk of vertical transmission of hepatitis C virus by breast milk. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999; 29: 1327-1329
689 Bortolotti F, Guido M, Zancan L. et al. Long-term outcome of hepatitis C in children. Hepatology 2004; 39: 1455 author reply 1455–1456
690 Broide E, Kimchi NA, Scapa E. Chronic hepatitis C infection in children. Minerva gastroenterologica e dietologica 2006; 52: 187-193
691 Goodman ZD, Makhlouf HR, Liu L. et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008; 47: 836-843
692 Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. Journal of gastroenterology and hepatology 2004; 19: 1357-1362
693 Barshes NR, Udell IW, Lee TC. et al. The natural history of hepatitis C virus in pediatric liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2006; 12: 1119-1123
694 Bortolotti F, Iorio R, Nebbia G. et al. Interferon treatment in children with chronic hepatitis C: long-lasting remission in responders, and risk for disease progression in non-responders. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2005; 37: 336-341
695 Rumbo C, Fawaz RL, Emre SH. et al. Hepatitis C in children: a quaternary referral center perspective. Journal of pediatric gastroenterology and nutrition 2006; 43: 209-216
696 Iorio R, Giannattasio A, Sepe A. et al. Chronic hepatitis C in childhood: an 18-year experience. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41: 1431-1437
697 Zuccotti GV, Torcoletti M, Salvini F. et al. Infants vertically infected with hepatitis C: a long term longitudinal follow-up. La Pediatria medica e chirurgica : Medical and surgical pediatrics 2004; 26: 50-52
698 Bortolotti F, Verucchi G, Camma C. et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134: 1900-1907
699 Slowik MK, Jhaveri R. Hepatitis B and C viruses in infants and young children. Seminars in pediatric infectious diseases 2005; 16: 296-305
700 Jara P, Hierro L, de la Vega A. et al. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. The Pediatric infectious disease journal 2008; 27: 142-148
701 Wirth S, Pieper-Boustani H, Lang T. et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 1013-1018
702 Wirth S, Ribes-Koninckx C, Calzado MA. et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 501-507
703 Sokal EM, Bourgois A, Stephenne X. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52: 827-831
704 Schwarz KB, Gonzalez-Peralta RP, Murray KF. et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140: 450-458 e451
705 Kelly DA, Haber B, Gonzalez-Peralta RP. et al. Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin. Journal of viral hepatitis 2012; 19: 263-270
706 Leung DH, Yao B, Viani RM. et al. ZIRCON: pharmacokinetics, safety, and efficacy of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in adolescents with genotype 1 or 4 hepatitis C virus infection. Journal of hepatology 2017; 66: S300-S301
707 Murray KF, Balistreri W, Bansal S. et al. Ledipasvir/sofosbuvir +/- ribavirin for 12 or 24 weeks is safe and effective in children 6–11 years old with chronic hepatitis C infection. Journal of hepatology 2017; 66: S57-S58
708 Urganci N, Gulec S, Dogan S. et al. Interferon and ribavirin treatment results of patients with HBV-HCV co-infection cured of childhood malignancies. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2006; 10: 453-457
709 Polywka S, Pembrey L, Tovo PA. et al. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. Journal of medical virology 2006; 78: 305-310
710 England K, Pembrey L, Tovo PA. et al. Excluding hepatitis C virus (HCV) infection by serology in young infants of HCV-infected mothers. Acta paediatrica 2005; 94: 444-450
711 Conte D, Fraquelli M, Prati D. et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000; 31: 751-755
712 Gervais A, Bacq Y, Bernuau J. et al. Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol 2000; 32: 293-299
713 Gibb DM, Goodall RL, Dunn DT. et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet (London, England) 2000; 356: 904-907
714 Okamoto M, Nagata I, Murakami J. et al. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. The Journal of infectious diseases 2000; 182: 1511-1514
715 Marine-Barjoan E, Berrebi A, Giordanengo V. et al. HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus?. Aids 2007; 21: 1811-1815
716 Hayashida A, Inaba N, Oshima K. et al. Re-evaluation of the true rate of hepatitis C virus mother-to-child transmission and its novel risk factors based on our two prospective studies. The journal of obstetrics and gynaecology research 2007; 33: 417-422
717 Mast EE, Hwang LY, Seto DS. et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. The Journal of infectious diseases 2005; 192: 1880-1889
718 Steininger C, Kundi M, Jatzko G. et al. Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. The Journal of infectious diseases 2003; 187: 345-351
719 Pappalardo BL. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. International journal of epidemiology 2003; 32: 727-734
720 Ohto H, Terazawa S, Sasaki N. et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. The New England journal of medicine 1994; 330: 744-750
721 Ceci O, Margiotta M, Marello F. et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. Journal of pediatric gastroenterology and nutrition 2001; 33: 570-575
722 Dal Molin G, D’Agaro P, Ansaldi F. et al. Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of viral load and IgM Anti-HCV as risk factors. Journal of medical virology 2002; 67: 137-142
723 European Paediatric Hepatitis CVN. A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection. The Journal of infectious diseases 2005; 192: 1872-1879
724 Tovo PA, Palomba E, Ferraris G. et al. Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997; 25: 1121-1124
725 Zanetti AR, Tanzi E, Romano L. et al. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology 1998; 41: 208-212
726 Boxall E, Baumann K, Price N. et al. Discordant outcome of perinatal transmission of hepatitis C in twin pregnancies. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2007; 38: 91-95
727 European Paediatric Hepatitis CVN. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network. BJOG : an international journal of obstetrics and gynaecology 2001; 108: 371-377
728 Inui A, Fujisawa T, Sogo T. et al. Different outcomes of vertical transmission of hepatitis C virus in a twin pregnancy. Journal of gastroenterology and hepatology 2002; 17: 617-619
729 Barlow KM, Mok JY. Dizygotic twins discordant for HIV and hepatitis C virus. Archives of disease in childhood 1993; 68: 507
730 Bhola K, McGuire W. Does avoidance of breast feeding reduce mother-to-infant transmission of hepatitis C virus infection?. Archives of disease in childhood 2007; 92: 365-366
731 Polywka S, Feucht H, Laufs R. Die chronische Hepatitis C der Mutter ist keine Kontraindikation für das Stillen. Bundesgesundheitsblatt 2003; 46: 739-743
732 Resti M, Azzari C, Mannelli F. et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. Bmj 1998; 317: 437-441
733 Zanetti AR, Tanzi E, Paccagnini S. et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet (London, England) 1995; 345: 289-291
734 Marcellin P, Alberti A, Dusheiko G. et al. EASL International Consensus Conference on Hepatitis C – Paris, 26–27 February 1999 – Consensus statement (Reprinted from Journal of Hematology, vol 30, pg 956–961, 1999). Journal of hepatology 1999; 31: 3-8
735 [Anonym]. Empfehlung des Bundesinstitutes für Risikobewertung. Ergänzung zu den Empfehlungen der Nationalen Stillkommission zu Hepatitis C und Stillen vom März 2001. Bundesgesundheitsblatt 2003; 46: 790